[COMPANY_001] Research and Development
LCZ696
Clinical Trial Protocol CLCZ696DUS01 / [STUDY_ID_REMOVED]
A multicenter, randomized, double- blind, double -dummy , 
parallel group, activ e controlled study to ev aluate the effect 
of sacubitril/v alsartan (LCZ696) v ersus v alsartan on 
changes in NT -proBNP, safety , and tolerability in HFpEF 
patients w ith a WHF ev ent (HFpEF decompensation) who 
have been stabilized and initiated at the time of or within [ADDRESS_904046] -decompens ation (PARAGLIDE -HF)
Document type: Amended Protocol Version (Clean )
EUDRACT number:Not applicable
Version number: V04
Clinical trial phase: IIIB
Release date: 08-Dec-2021

[COMPANY_001] Page 2
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Table of contents
Table of contents ........................................................................................................................ [ADDRESS_904047] of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 9
Protocol summary .............................................................................................................. 11
1Introduction ....................................................................................................................... 18
1.1 Background ............................................................................................................ 18
1.2
Rationale for Protocol Amendme nts..................................................................... 19
1.3 Changes to Protocol ............................................................................................... 20
1.4 Purpose .................................................................................................................. 21
2Objectives and endpoints ................................ ................................ ................................ ...22
3Study  design ...................................................................................................................... 24
4Rationale ............................................................................................................................ 25
4.1 Rationale for stud y design ..................................................................................... 25
4.2 Rationale fo r dose/regimen and duration of treatment
.......................................... 26
4.3
Rationale for choice of comparator ....................................................................... 26
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..27
4.5 Risks and benefits .................................................................................................. 27
5Population ................................ ................................ ................................ .......................... 27
5.1 Inclusion criteria .................................................................................................... 28
5.2 Exclusion criteria ................................................................................................... 29
6Treatment ........................................................................................................................... 31
6.1 Study  treatment Investigational and control drugs
................................................ 31
6.1.1 Treatment arms/group ........................................................................... 33
6.1.2 Treatment duration ................................................................................ 33
6.1.3 Concomitant therap y
............................................................................. 33
6.1.4
Prohibited medication ........................................................................... 34
6.1.5
Rescue medication ................................................................................ 35
6.2 Patient numbering, treatment assignment, randomization ..................................... 35
6.2.1
Patient numbering ................................................................................. 35
6.2.2 Treatment assignment, randomization .................................................. 35
6.3 Treatment blinding ................................................................................................. 36
6.4 Dose modification .................................................................................................. 37

[COMPANY_001] Page 3
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
6.4.1 Dose modifications................................................................................ 37
6.4.2 Follow-up for angioedema .................................................................... 39
6.5 Additional treatment guidance............................................................................... 39
6.5.1 Treatment compliance........................................................................... 39
6.5.2 Emergency breaking of assigned treatment code.................................. 39
6.6 Preparation and dispensation ................................................................................. 40
6.6.1 Handling of study treatment and additional treatment.......................... 40
6.6.2 Instruction for prescribing and taking study treatment ......................... 41
7 Informed consent procedures ............................................................................................ 43
8 Visit schedule and assessments ......................................................................................... 44
8.1 Screening ............................................................................................................... 50
8.1.1 Information to be collected on screening failures ................................. 50
8.2 Patient demographics/other baseline characteristics ............................................. 50
8.3 Efficacy.................................................................................................................. 50
8.3.1 Heart failure signs and symptoms......................................................... 51
8.3.2 Estimated glomerular filtration rate (eGFR)......................................... 51
8.3.3 Biomarkers ............................................................................................ 52
8.3.4 Appropriateness of efficacy assessments .............................................. 52
8.4 Safety ..................................................................................................................... 52
8.4.1 Laboratory evaluations.......................................................................... 54
8.4.2 Electrocardiogram (ECG) ..................................................................... [ADDRESS_904048]-study treatment .......................................................... 59
10 Safety monitoring and reporting........................................................................................ 59
10.1 Definition of adverse events and reporting requirements...................................... 59PP
DPP
D
[COMPANY_001] Page 4
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
10.1.1 Adverse events ...................................................................................... 59
10.1.2 Serious adverse events .......................................................................... 61
10.1.3 SAE reporting........................................................................................ 62
10.1.4 Pregnancy reporting .............................................................................. 62
10.1.5 Reporting of study treatment errors including misuse/abuse................ 63
10.2 Additional Safety Monitoring................................................................................ 63
10.2.1 Reporting angioedema-like events........................................................ 63
10.2.2 Data Monitoring Committee ................................................................. 64
10.2.3 Steering Committee............................................................................... 64
10.2.4 Adjudication committees ...................................................................... 64
11 Data collection and database management........................................................................ 65
11.1 Data collection....................................................................................................... 65
11.2 Database management and quality control ............................................................ 65
11.3 Site monitoring ...................................................................................................... 66
12 Data analysis and statistical methods ................................................................................ 66
12.1 Analysis sets .......................................................................................................... 67
12.2 Patient demographics and other baseline characteristics....................................... 67
12.3 Treatments ............................................................................................................. 67
12.4 Analysis of th e primary endpoint .......................................................................... 68
12.4.1 Analysis of th e primary endpoint.......................................................... 68
12.4.2 Handling of missing values/censoring/discontinuations....................... 68
12.4.3 Sensitivity and Supplementary Analyses .............................................. 68
12.5 Analysis of Sec ondary E ndpoints.......................................................................... 69
12.5.1 Secondary endpoints ............................................................................. 69
12.5.2 Safety endpoints.................................................................................... 72
12.5.3 Biomarkers ............................................................................................ 73
7373
12.7 Interim analysis...................................................................................................... 75
12.8 Sample size and Power .......................................................................................... 75
13 Ethical considerations and administrative procedures ...................................................... 75
13.1 Regulatory and ethical compliance........................................................................ 75
13.2 Responsibilities of the investigator and IRB/IEC.................................................. 76
13.3 Publication of study protocol and results............................................................... 76
13.4 Quality Control and Quality Assurance................................................................. 76[COMPANY_003][COMPANY_003]
[COMPANY_001] Page 5
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
14Protocol adherence ................................ ................................ ................................ ............ 76
14.1 Protocol amendments ............................................................................................. 77
15References ......................................................................................................................... 78
16Appendices ........................................................................................................................ 80
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 80
16.2 Appendix 2: Treatment guidelines for h yperkalemia (serum potass ium greater 
than or equal to 5.5 mEq/L) ................................................................................... 81
16.3
Appendix 3: Guidelines for the management of blood pressure ........................... 83
16.4 Appendix 4: Guidelines for the management of renal dy sfunction ....................... 83
16.5 Appendix 5: Expanded Assessment Schedule ....................................................... [ADDRESS_904049] of tables
Table 2
-1 Objectives and related endpoints .......................................................... 22
Table 6
-1 Investigational and control drug............................................................ 31
Table 6
-2 Treatment Dose Levels ......................................................................... 32
Table 6
-3 Prohibited medication ........................................................................... 34
Table 6
-4 Definition of low and high total daily  doses for commonly  used 
ACEI s and ARBs .................................................................................. 42
Table 6
-5 Starting dose of stud y medication ......................................................... 42
Table 8
-1 Assessment Schedule ............................................................................ 46
Table 8
-2 Assessments & Specifications............................................................... 53
Table 8-3 Laboratory  Assessments ........................................................................ 55
Table 10
-1 Guidance for capturing the study  treatment errors i ncluding 
misuse/abuse ......................................................................................... [ADDRESS_904050] of figures
Figure 3 -
1 Study  Design ......................................................................................... 24

[COMPANY_001] Page 6
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
List of abbreviations
AC Adjudication committee
ACE angiotensin converting enzy me
ACEI angiotensin converting enzy me inhibitor
ADHF acute decompensated heart failure
AE adverse event
AF atrial fibrillation
AHF acute heart failure
ALT alanine aminotransferase
ANCOVA analysis of covariance 
ANP atrialnatriuretic peptide
ARB angiotensin receptor blocker
ARNI angiotensin receptor neprilysin inhibitor
AST aspartate aminotransferase
AT1 angiotensin type 1
ATC Anatomical Therapeutic Chemical
BID twice a day
BMI Body mass index
BNP B-type natriuretic peptide
BP blood pressure
bpm beats per minute
BUN Blood urea nitrogen
CABG Coronar y artery by[CONTACT_669433]&PS Chief Medical Office and Patient Safety
COPD Chronic obstructive pulmonary disease
COVID -19 COronaVIrus Disease 2019
COX -2 cyclo-oxygenase -2
CPK creatine phosphokinase
CRA clinical research associate (site monitor)
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CRT Cardiac resynchronization therapy 
CTT Clinical trial team
CV cardiovascular
DBP diastolic blood pressure
DM diabetes mellitus
DMC Data Monitoring Committee

[COMPANY_001] Page 7
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
EAC Endpoint Adjudication Committee
ECG Electrocardiogram
Echo echocardiogram
eCRF electronic case report form
ED Emergency Department
EDC Electronic Data Capture
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
cGMP cyclic guanosine monophosphate
EMA European Medicines Agency
ER emergency room
EU European
FAS full analysis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GCS Global Clinical Supply
HF heart failure
HFrEF heart failure with reduced ejection fraction
HFpEF Heart failure with preserved ejection fraction
Hgb hemoglobin
hs-Troponin high sensitivity troponin
HTN hypertension
IB Investigator’s brochure
ICF Informed consent form
ICH International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use
IEC Independent Ethics Committee
IN investigator notification
IV intravenous
IRB Institutional Review Board
IRT Interactive Response Technology
LS least squared
LVAD left ventricular assist device
LVEF left ventricular ejection fraction
MDRD Modification of Diet in Renal Disease
MedDRA Medical dictionary for regulatory activities 
MI myocardial infarction
mm Hg millimeters of mercury
NEP neutral endopeptidase[COMPANY_003]
[COMPANY_001] Page 8
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
NSAID non-steroidal anti -inflammatory drug
NT-proBNP N-terminal pro -brain natriuretic peptide
NYHA [LOCATION_001] Heart Association
PCI percutaneous coronary intervention
QMS Quality Management System
RAN Randomized Analy sis Set
RAS renin angiotensin system ; randomize analy sis set (statistics)
RASi Renin angiotensin s ystem inhibition
RBC red blood cell
RR relative risk
SAE serious adverse event
SAF safety set
SAP Statistical Analysis Plan
SBP systolic blood pressure
SD Standard Deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic py ruvic transaminase
SOP standard operating procedure
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
USPI [INVESTIGATOR_146442]/package insert
WBC white blood cell(s)
WHF Worsening heart failure
WHO World Health Organization 

[COMPANY_001] Page 9
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as described in the 
protocol, but not as an investigational medicinal product (e.g. any background 
therapy)
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study patient
Cohort A specific group of patient s fulfilling certain criteria and generally treated at the same 
time
Control drug A  stu dy drug (active or placebo) used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Cycles Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g., q28 days)
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data 
using data collection systems, such as W eb-based applications, interactive voice 
response systems and clinical laboratory interfaces. EDC includes the use of 
Electronic Case Report Forms (eCRFs) which a re used to capture data transcribed 
from paper source forms used at the point of care
End of the clinical trial The end of the clinical trial is defined as the last visit of the last patient or at a later 
point in time as defined by [CONTACT_201667]/time of patient entry into the study at which informed consent must be obtained 
Investigational drug/
treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication bottles
Mis-randomized 
patient sMis-randomized patient s are those who were not qualified for randomization and 
who did not take study treatment, but have been inadvertently randomized into the 
study
Other treatment Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy)
Part A sub -division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple 
dose part, o r a part in patient s with established disease and in those with newly-
diagnosed disease
Patient An individual with the condition of interest for the study
Patient number A unique number assigned to each patient upon signing the informed consent. This 
number is the definitive, unique identifier for the patient and should be used to 
identify the patient throughout the study for all data collected, sample labels, etc.
Period The subdivisions of the trial design ( e.g. Screening, Treatment, Follow -up) which are 
described in the Protocol. Periods define the study phases and will be used in 
clinical trial database setup and eventually in analysis
Perpetrator drug A drug which affects the pharmacokinetics of the other drug
Personal data Patient information collected by [CONTACT_201039]. This data includes patient identifier information, study 
information and biological samples. 
Premature patient
withdrawalPoint/time when the patient exits from the study prior to the planned completion of all 
study drug administration and/or assessments; at this time all study drug 
administration is discontinued and no further assessments are planned
Randomization number A unique identifier assigned to each randomized patient

[COMPANY_001] Page 10
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Screen Failure A patient who did not meet one or more criteria that were required for participation in 
the study
Source Data/Document Source data refers to the initial record, d ocument, or primary location from where 
data comes. The data source can be a database, a dataset, a spreadsheet or even 
hard-coded data, such as paper or eSource
Start of the clinical trial The start of the clinical trial is defined as the signature [CONTACT_35596] e informed consent by 
[CONTACT_669434](s) prior to the 
defined study treatment completion date (if any) for any reason; may or may not also 
be the point/time of study discontinuation 
Subject A trial participant (can be a healthy volunteer or a p atient)
Treatment arm/group A treatment arm/group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts.
Variable A measured value or assessed response that is determined from specific 
assessments and used in data analysis to evaluate the drug being tested in the 
study
Withdrawal of study 
consent ( WoC)Withdrawal of consent from the study occurs only when a patient does not want to 
participate in the study any longer and does not allow any further collection of 
personal data 

[COMPANY_001] Page 11
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Protocol summary
Protocol number CLCZ696DUS01
Full Title A multicenter, randomized, double- blind, double -dummy, parallel group, 
active controlled study to evaluate the effect of sacubitril/valsartan 
(LCZ696) versus valsartan on changes in NT-proBNP, safety, and 
tolerability in HFpEF patients with a WHF event (HFpEF 
decompensation) who have been stabilized and initiated at the time of
or within [ADDRESS_904051]-decompensation (PARAGLIDE -HF)
Brief title Prospective comparison of ARNI with ARB Given following 
stabiLization In DEcompensated HFpEF (PARAGLIDE -HF)
Sponsor and Clinical 
Phase[COMPANY_001], Phase IIIB
Investigation type Drug
Study type Interventional
Purpose and rationale The purpose of this study is to assess the effect of sacubitril/valsartan 
vs. valsartan on changes in NT -proBNP ,safety ,and tolerability in 
HFpEF patients with a WHF event ( HFpEF decompensation) who have 
been stabilized and initiated at the time of or within [ADDRESS_904052]-
decompensation
Primary Objective(s) To demonstrate the effect of sacubitril/valsartan vs. valsartan on time-
averaged proportional change in NT-proBNP from baseline to Weeks 4 
and 8 in HFpEF patients with a WHF event (HFpEF decompe nsation)
who have been stabilized for and initiated at the time of or within [ADDRESS_904053]-decompensation
Secondary ObjectivesTo determine the effect of sacubitril/valsartan vs. valsartan on the 
composite hierarchical outcome consisti ng of: a) time to CV death, 
b) total HF hospi[INVESTIGATOR_059] s, c) total urgent HF visit s, and d) time -
averaged proportional change in NT -proBNP (from baseline to 
Weeks 4 and 8 ) using win ratio methodology
To assess the effect of sacubitril/valsartan vs. valsartan on t otal 
composite events based on CV death, HF hospi[INVESTIGATOR_602], and 
urgent HF visits
To assess the effect of sacubitril/valsartan vs. valsartan on the 
incidences of a composite endpoint of worsening renal function 
(renal death, reaching ESRD, or > 50% decline in eGFR relative to 
baseline
To assess the effect of sacubitril/valsartan vs. valsartan on change 
in NT -proBNP from baseline to Week 8 
To assess the effect of sacubitril/valsartan vs. valsartan on change 
from baseline in hs -Troponin (high sensitiv ity) at Weeks 4 and 8
To assess  the effect of sacubitril/valsartan vs. valsartan on 
tolerability and the incidence of adverse events of special interest 
during treatment
Study design This study will use a randomized, double -blind, double -dummy , active -
controlled, parallel group design. Eligible patients will be randomized 
either during hospi[INVESTIGATOR_272],or within 30 daysof, a WHF event

[COMPANY_001] Page 12
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
(HFpEF decompensation) .A WHF event ( HFpEF decompensation) is 
defined as a hospi[INVESTIGATOR_059], emergency department (ED) visit or out -of-
hospi[INVESTIGATOR_669374] ,all requiring IV diuretics.
Randomized patients will have been hemody namically stabilized ,
defined in this study as: 
SBP ≥100mmHg for the preceding 6 hours prior to 
randomization; no sy mptomatic hypotension 
No increase (intensification) in IVdiuretic dose within last 6 
hours prior to randomization
No IV inotropic drugs for 24 hours prior to randomization
No IVvasodilators including nitrates within last 6 hours prior to 
randomization
All patients will need to meet all inclusion and none of the exclusion 
criteria.  
Patients will be randomized 1:1 to sacubitril/valsartan or valsartan. Initial 
dose at randomization will be determined based on the patient’s previous 
dose ofor lack ofACEi/ARB immediately prior to current WHF event  
(HFpEF decompensation ), or at the time of post-decompensation
randomization.
Patients currently or recently  taking ACEi : In order to provide for a 
necessary 36-hour washout of prior ACEi treatment before receiving 
sacubitril/valsartan, eligible patients will be randomized no earlier than 
[ADDRESS_904054] ACEi dose).  Hospi[INVESTIGATOR_669375] 36hours prior to 
randomization and the first dose of study medication.  
The maximum duration of study for the first patient randomized after 
amendm ent1is approximately 20 months;the anticipated minimum 
follow -up would be for [ADDRESS_904055] of male and female patients, ≥ 18years 
of age, current ly hospi[INVESTIGATOR_669376] 30 daysof a WHF event 
(HFpEF decompensation). A WHF event (HFpEF decompensation) is 
defined as a hospi[INVESTIGATOR_059], emergency department ( ED) visit or out -of-
hospi[INVESTIGATOR_669374], allrequiring IV diuretics. A total of approximately 
450patients will be randomized to sacubitril/valsartan or valsartan in a 
1:[ADDRESS_904056] been hemodynamically stabilized defined 
in this study as: 
SBP ≥100mmHg for the preceding 6 hours prior to 
randomization; no sy mptomatic hypotension 
No increase (intensification) in IVdiuretic dose within last 6 
hours prior to randomi zation
No IV inotropic drugs for 24 hours prior to randomization
No IVvasodilators including nitrates within last 6 hours prior to 
randomization

[COMPANY_001] Page 13
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
All patients will need to meet all other inclusion and none of the exclusion 
criteria.
Key Inclusion criteria1.Signed informed consent must be obtained prior to participation in 
the study
2.Patients ≥ 18years of age, male or female
3.Current hospi[INVESTIGATOR_272] W HF (HFpEF decompensation), or within 
30 days of discharge following a WHF event (defined as 
hospi[INVESTIGATOR_059], emergency department (ED) visit or out-of-hospi[INVESTIGATOR_669377], allrequiring IV diuretics) . Patients with a diagnosis 
of acute heart failure had to have symptoms and signs of fluid 
overload (i.e. jugular venous distention, edema or rales on 
auscultation or pulmonary congestion on chest x-ray). Eligible 
patients will be randomized after IV diuresis for HFpEF is given (and 
no earlier than [ADDRESS_904057] ACEi dose if applicable) and 
within [ADDRESS_904058]-decompensation after presentation with acute 
HFpEF decompensation and meeting the following definitions of 
hemodynam ic stability:
Randomized patients will have been hemodynamically stable defined in 
this study as: 
a.SBP ≥100mmHg for the preceding 6 hours prior to 
randomization; no sy mptomatic hypotension 
b.No increase (intensification) in IVdiuretic dose within 
last [ADDRESS_904059] recent LVEF >40% (within past 3 months)
5.Elevated NT -proBNP or BNP at the time of acute HFpEF 
decompensation or post -decompensation screening (and within 72 
hours forout-of-hospi[INVESTIGATOR_392269], if applicable): 
a.Patients not in AF at the time of biomarker 
assessment: NT -proBNP ≥ 500pg/mL or BNP ≥ 150 
pg/mL; patients in AF at the time of biomarker 
assessment: NT -proBNP ≥ 1000pg/mL or BNP ≥ 300 
pg/mL
b.Patients recruited in-hospi[INVESTIGATOR_669378]-hospi[INVESTIGATOR_669379]-proBNP 
or BNP value.
c.Patients enrolled post-decompensation can be 
randomized based on their NT -proBNP or BNP value 
in the following way:
i.if enrolling in post -decompensation setting 
then need eligible screening/local NT -
proBNP/BNP within [ADDRESS_904060] value could be from recent 
hospi[INVESTIGATOR_669380] 72 hours or 
ii.would require (re) drawing NT -proBNP or BNP 
labs in post -decompensation setting if the lab
value is not already available with in the last 72 
hours).

[COMPANY_001] Page 14
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
6.Has not taken an ACEi for 36 hours prior to randomization
Key Exclusion criteria 1)Any clinical event within the [ADDRESS_904061] reduced the LVEF (i.e., MI, CABG), unless an echo 
measurement was performed after the event confirm ing the LVEF to 
be >40%
2)Entresto™ (sacubitril/valsartan) usage within the past 60 day s
3)eGFR < 20ml/min/1.73 m2 as measured by [CONTACT_669435] (MDRD) formula at most recent 
assessment prior to randomization and within 24 hours prior to
inpatient randomization or 72 hours prior to outpatient randomization
4)Serum potassium > 5.2 mEq/L at most recent assessment prior to 
randomization and within 24 hours prior toinpatient randomization
or 72 hours prior to outpatient randomization
5)Acute coronar y syndrome, stroke, transient ischemic attack; cardiac, 
carotid or other major CV surgery; percutaneous coronary 
intervention (PCI) or carotid angioplasty, within 30 days prior to
randomization
6)Probable alternative diagnoses that in the opi[INVESTIGATOR_3078] n of the investigator 
could account for the patient’s HF symptoms (i.e. dyspnea, fatigue) 
such as significant pulmonary disease (including primary pulmonary 
HTN), anemia or obesity. 
7)Isolated right HF in the absence of left-sided structural heart disease
8)History of hypersensitivity (i.e. including angioedema), known or 
suspected contraindications, or intolerance to any of the study  drugs 
including ARNIs (i.e. sacubitril/valsartan), and/or ARBs
9)Patients with a known history of angioedema due to any etiology
10)Patients with a history  of heart transplant or LVAD, currently  on the 
transplant list, or with planned intent to im plant LVAD or CRT device 
within the initial three months of enrollment during the trial 
11)A cardiac or non-cardiac medical condition other than HF with an 
estimated life expectanc y of < 6months
12)Known pericardial constriction, genetic hypertrophic 
cardiom yopathy, or infiltrative cardiom yopathy including suspected 
or confirmed amyloid heart disease (am yloidosis)
13)Life-threatening or uncontrolled d ysrhythm ia, including 
symptomatic or sustained ventricular tachycardia and atrial 
fibrillation or flutter with a resting ventricular rate >110 bpm
14)Clinically significant congenital heart disease felt to be the cause of 
the patient’s sy mptoms and signs of HF
15)Coronar y or carotid artery disease or valvular heart disease likely 
to require surgical or percutaneous intervention within the duration 
of the trial 
16)Any surgical or medical condition, which in the opi[INVESTIGATOR_1070], may place the patient at higher risk from his/her 
participation in the study, or is likely to prevent the patient from 
complying with the requirements of the study or completing the 
study
17)Known hepatic impairment (as evidenced by [CONTACT_146499] > 3 
mg/dL, or increased ammonia levels, if performed), or history of 
cirrhosis with evidence of portal hypertension such as varices

[COMPANY_001] Page 15
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
18)Participation in any other clinical trial involving investigational 
agents or devices within the past 30 days
19)Current confirmed COVID19 infection
20)Past COVID19 infection with persistent sy mptom burden suspected 
due to COVID19 (further defined in Section 5.2 ).
21)Pregnant or nursing (lactating) wom en, where preg nancy  is defined 
as the state of a female after co nception and until the termination of 
gestation, confirmed by a positive hCG laboratory test.
22)Women of child- bearing potential, defined as all women 
physiologically capable of becoming pregnant, unless they are 
using highly effective methods of contraception during dosing of 
investigational drug and for 7 days off of study drug . Highly 
effective contraception methods are defined in Section 5.2 .
Study treatment All eligible patients will be randomiz ed to receive either 
sacubitril/valsartan or valsartan.  The following treatment will be provided 
(double -blind, double dummy ) until the last patient randomized is 
followed for 8 weeks: 
Dose 
LevelSacubitril/valsartan Valsartan
1 24/26 mg [50mg] BID 40 mg BID
2 49/51 mg [100mg] BID 80 mg BID
3 97/103 mg [200 mg] BID 160 mg BID
Sacubitril/valsartan with matching placebo and valsartan with matching 
placebo will be provided for the double -blind treatment period.
Initial dose at randomization will be determined based on the patient’s 
previous dose of or lack of ACEi/ARB immediately prior to current WHF 
event ( HFpEF decompensation ), or at the time of post-decompensation
randomization. .  Every attempt should be m ade to titrate to and maintain 
patients ontarget study  drug Dose Level 3 for as long as possible 
throughout the study .
Key safety 
assessmentsIncidence of worsening renal function, defined as an increase in 
serum creatinine of ≥0.5mg/dl and worsening of the eGFR by [CONTACT_12697] 25% 
Incidence of sy mptomatic hypotension 
Incidence of hyperkalemia (potassium >5.5 mEq/l)
Incidence of angioedema 
Safety assessments will consist of monitoring and recording of all 
adverse events and serious adverse events, evaluation of hematology, 
blood ch emistry and urine values, regular measurement of vital signs 
and the performance of physical examinations.
Sample Size and power The target sample size for this study is approximately 450total 
patients, randomized in the two treatment groups in 1:1 rati o. The 
maximum planned duration of follow -up after randomization (for 
patients enrolled under Amendment 1 or later ) is approximately 20 
months; the anticipated minimum follow -up would be for 8 weeks.  The 

[COMPANY_001] Page 16
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
power of the study is determined based on these 450patients for the 
primary  endpoint . 
Power for the primary endpoint
This sample size of 450patients would have 85% power to detect a 
23% reduction in the geometric mean of the proportional change from 
baseline to an average of W eeks 4 and 8 in NT -proBNP for the 
sacubitril/valsartan treatment group. The power is estimated assuming 
a two -sided significance level of 0.[ADDRESS_904062] deviation of 
0.85 for change in log transformed NT -proBNP and a 15% rate of 
missingness of NT -proBNP at baseline or b oth W eek 4 and W eek 8.
nQuery Version [IP_ADDRESS] (2019) software package is used in calculating 
the power of the test.
Data analysis The Full Analysis Set (FAS) comprises all participants to whom  study 
treatment has been assigned by  [CONTACT_669436]. According to the intent -
to-treat principle, participants will be included for analysis according to 
the treatment they have been assigned to during the randomization 
procedure.
The patients in this trial are divided in two groups, (1) Those who are 
randomized under Protocol Version 00 (Original Protocol patients) and 
(2) Those who are randomized under Protocol Version 01 or later .  FAS 
includes patients from both groups. See Section 3 for details.
Analysis of the primary endp oint
The primary null hypothesis (H10) to be tested is that the ratio of the 
geom etric means of NT-proBNP (average of Weeks 4 and 8) divided 
by [CONTACT_669437]/valsartan and valsartan groups are equal 
versus the alternative hypothesis (H1a) that the ratio of the geometric 
means of NT -proBNP are not equal.
First, the arithmetic mean of NT -proBNP at Weeks 4 and 8 will be 
calculated, then the change from baseline in natural log-transformed 
NT-proBNP will be calculated as follows: ln(mean post dose value) –
ln(baseline value). The natural logarithm will be used in all these 
calculations. This log -transformed value will be used as the dependent 
variable in the analy sis of covariance (ANCOVA) model described 
below. This dependent variable is calle d, the time -averaged 
proportional change from baseline in logarithmic scale. The dependent 
variable will be analyzed using an ANCOVA model with treatment in -
/out-of-hospi[INVESTIGATOR_392269] , gender, race, baseline LVEF (<=57%, 
>57%) as fixed effect factors , age and the logarithmic baseline NT -
proBNP as covariate s.
The treatment effect in terms of ratios of geometric means is 
estimated based on the least -squared means (LS -means) from the 
ANCOVA model and the corresponding two -sided 95% confidence 
interval will be provided .Geometric means will be calculated by 
[CONTACT_669438] -means based on the fitted 
ANCOVA model.

[COMPANY_001] Page 17
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
Interim analysis:
There is no planned interim analysis for efficacy in the study. 
An independent Data Monitoring Committee (DMC) will be responsible 
for performing interim safety assessment using independent statistician 
and programmer who will not be involved in the trial conduct. The DMC 
charter will contain the committee’s responsibilities regarding the interim safety assessment. Details of this safety assessment will be included in the Statistical Analysis Plan.
Interim safety assessments are planned to be performed during the 
study and results will be provided to DMC for their review and 
recommendation.  The number and/or timing of these safety assessments will be mentioned in the Data Monitoring Committee Charter. No adjustment of the level of significance will be made for these interim safety assessments.
SeeSection 12 for additional information on planned data analyses.
Key words Heart failure with preserved ejection fraction, HFpEF, heart failure 
hospi[INVESTIGATOR_059], NYHA, NT-proBNP, win ratio, acute decompensated heart failure, sacubitril/valsartan,  
 Worsening heart failure (WHF), heart failure 
decompensation[COMPANY_003]
[COMPANY_001] Page 18
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
1 Introduction
1.1 Background
Sacubitril/valsartan is a first-in-class angiotensin receptor -neprily sin inhibitor (ARNI). The 
PARAMOUNT and PARAGON -HFtrials provided information regarding theeffect of
sacubitril/valsartan compared with valsartan on clinical outcomes in patients with chronic heart 
failure with preserved ejection fraction (HFpEF), initiating treatment in the outpatient setting 
(Solomon et al 2012; Solomon et al 2019 ).Further data are needed regarding the use of 
sacubitril/valsartan in patients hospi[INVESTIGATOR_669381] -HF, includ ing newl y diagnosed, morbidl y 
obese, recently  hospi[INVESTIGATOR_057], and Black patients. PARAGLIDE -HFwill provide important 
information regarding the efficacy , 
safet y, and tolerability  of initiating sacubitril/valsartan 
therap y in patients with a WHF event (HFpEF decompensation) who have been 
hemody namicall y stabilized during a hospi[INVESTIGATOR_669382].
Sacubitril/valsartan has been evaluated for efficacy  andsafet y in ambulatory  patients with 
chronic HFpEF. The PARAMOUNT study  was a randomized, double -blind, active -controlled 
phase 2 trial of 308 patients with HFpEF (Left ventricular ejection fraction (LVEF) ≥45%) 
(Solomon et al 2012). Patients enrolled in the study  received sacubitril/valsartan titrated to 
97/103 mgtwice daily orvalsartan titrated to160mgtwice daily.Theprimary endpoint, change 
in NT-proBNP levels from baseline to 12 weeks, was significantly reduced inthe
sacubitril/valsartan group compared with thevalsartan group (sacubitril/valsa rtan: baseline, 783
pg/mL [95% CI670-914], 12weeks 605 pg/mL  [95% CI512 -714]; valsartan: baseline, 862 
pg/mL [95% CI 733-1012], 12 weeks 835 pg/mL [95% CI 710-981]; ratio of change from 
baseline: sacubitril/valsartan / valsartan, 0.77, 95% CI 0.64 -0.92, p=0.005. Sacubitril/valsartan 
was well tolerated and had a similar adverse effect profile compared to valsartan.  
In PARAGON -HF, a randomized, double -blind, active -controlled phase 3 trial with 4822 
ambulatory  chronic HFpEF patients, the primary  endpoint was a composite of total 
hospi[INVESTIGATOR_669383].  After a single blind run-
in period, patients w ere randomized to either sacubitril/valsartan or valsartan at target doses of 
97/103mg or 160mg twice daily , respectively , and were followed for a median duration of 35 
months.  There were 894 (12.8 per 100 patient -years) primary  composite events (CEC -
confirmed total heart failure hospi[INVESTIGATOR_669384]) in the sacubitril/valsartan group 
compared to 1009 (14.6 per 100 patient -years) in the valsartan group, indicating a 13% relative 
rate reduction inthe primary  composite endpoint, a treatment effect that narrowl y missed 
statistical significance (RR=0.87; 95% CI: 0.75- 1.01; p=0.0587) (Solomon et al 2019).   No new 
safet y signals were seen in PARAGON -HF, and safet y assessments were consistent with 
PARADIGM -HF, a HF with reduced ejection fraction study  comparing sacubitril/valsartan to 
enalapril ( McMurray  et al 2014 ).  
It has been reported that the period subsequent to a worsening heart failure event is when the 
patients are most vulnerable for hospi[INVESTIGATOR_059], re-hospi[INVESTIGATOR_059] s
,and increased mortality. In 
a post-hoc analysis of PARAGON -HF, those HFpEF patients who were recentl y hospi[INVESTIGATOR_669385] a 2-3 fold higher risk of rehospi[INVESTIGATOR_669386]. Of the 4796 patients

[COMPANY_001] Page 19
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
randomiz edand included in the full analysis set (FAS), 48% had a hospi[INVESTIGATOR_669387] -HF.   Moreover, 622 (13% of the total randomized) 
patients had had at least one hospi[INVESTIGATOR_21342] 30 days of trial screening. The event rate 
was 26.7 ( ≤30 day s) vs. 7.9 (not previously  hospi[INVESTIGATOR_057]) per 100 patient -years in the valsartan 
group.  In comparison, the absolute risk reduction for patients enrolled at ≤ 30 days after 
hospi[INVESTIGATOR_40175] 6.4% in the group receiving sacubitr il/valsartan compared to valsartan and 
this effect decreased as time from hospi[INVESTIGATOR_669388] (Vaduganathan et al 2019 ).  
HFpEF patients with ADHF are known to have markedl y elevated levels of BNP and NT-
proBNP, which are reduced following adequate treatment and normalization of their cardiac 
decompensation. In the I
-PRESERVE trial, patients with both a recent hospi[INVESTIGATOR_669389] -ProBNP (> 360 pg/mL) had a greater risk of cardiovascular death and subsequent 
heart failure hospi[INVESTIGATOR_059] (Kristensen et al 2015 ). Therefore, it is important to evaluate 
therapeutic strategies thatcanleadtosuperior reductions inNT-proBNP inpatients hospi[INVESTIGATOR_669390].
The PI[INVESTIGATOR_15597] -HF trial evaluated the effect of in-hospi[INVESTIGATOR_146444]/valsartan vs. 
enalapril in patients with heart failure with reduced 
ejection fraction (HFrEF) who had been 
stabilized during hospi[INVESTIGATOR_146474]. PI[INVESTIGATOR_15597] -HF 
demonstrated greater reduction with sacubitril/valsartan vs. enalapril in time-averaged 
proportional change inNT-ProBNP from baseline toweeks 4and8(percent change, -46.7% vs.
-25.3%; ratio of change with sacubitril/valsartan vs. enalapril 0.71 [0.63 –0.81], p<0.001) and 
a decrease in the exploratory  clinical composite outcome of death, re-hospi[INVESTIGATOR_222885], LVAD implantation, or listing for cardiac transplant ( Velazquez et al 2018 ).
Based on the above, PARAGLIDE- HF isdesigned to assess the efficacy , safety  and tolerability 
of sacubitril/valsartan in HFpEF patients with a WHF event (HFpEF decompensation) who 
have been stabilized andinitiated at the time of or within [ADDRESS_904063]-decompensation .
These data from PARAGLIDE -HF willcomplement TRANSI TION and PI[INVESTIGATOR_15597] -HF, where 
both examined the safety  and efficacy  of sacubitril/valsartan in hospi[INVESTIGATOR_669391] y stabilized after an acute decompensated HFrEF event ( Wachter R et al 2018 , 
Velazquez et al 2018 ).
1.2 Rationale for Protocol A mendment s
Amendment 1 (January  2020)
PARAGLIDE- HF amendment 1reflects learnings from the PARAGON -HF trial, which was 
completed 3 months into PARAGLIDE -HF trial enrollment. From PARAGON -HF, learnings 
about hospi[INVESTIGATOR_669392] (HFpEF) patients helped guide 
additional key  endpoints as wel l as sample size, timeline, and duration of treatment changes.
Amendment 2 (September 2020)
Based on technology  advancement s, site-level changes, and regulatory  adjustments during the 
COVID -19 pandemic, Amendment 2 reflects allow ances for virtual visits, per patient stability 
and Investigator discretion, at time points defined in Section 8.

[COMPANY_001] Page 20
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
Amendment 3 (October 2020)
Amendment 3 corrects an administrative error identified within Amendment 2.  As described
in Amendment 2, Visit 14, based on patient stability and Investigator discretion, can be conducted virtually.  
 
 
Amendment 4 (December 2021)
Amendment [ADDRESS_904064] affected patients and research sites and negatively impacted study timelines. This amendment decreases the sample size (from 800 to 450 patients) to focus on the primary endpoint of changes from baseline in NT-proBNP and moves the key (clinical) secondary endpoints to traditional secondary endpoints due to the key secondary endpoints having reduced statistical power. Inclusion and exclusion criteria were adjusted based on a thorough examination of screening logs and discussions with investigators who noted that many patients with bona fide HFpEF were being excluded due to the stringent exclusion language (example, prior exclusion #6a, b, and c). These changes aim to increase the generalizability of the trial population to real world patients. In addition, a HFpEF patient with a WHF event (including a HF hospi[INVESTIGATOR_059], ED visit, or urgent HF visit, all requiring IV diuretics) within [ADDRESS_904065] a similar risk of future cardiovascular events to those hospi[INVESTIGATOR_669393].
1.3 Changes to Protocol
Changes to specific sections in the protocol are shown in the track changes version of the protocol using the strike through font for deletions and red underlined for insertions.
Amendment 1: Significant changes from Protocol Version 00 include:
!Addition of two key secondary endpoints that will assess clinical outcomes
!Increased sample size from 616 to approximately 800 patients (with increased study sites 
from 100 to approximately 130)
!Extended duration of treatment from 12 weeks (Original Protocol) to maximum of 
approximately 20 months and an average duration of study for all patients is anticipated to be approximately 11 months.
!Extended trial recruitment period extending to within [ADDRESS_904066]-discharge
!Some of the inclusion and exclusion criteria were changed/modified based on additional 
data from other analyses/publications or input from the Steering Committee/external experts.
!Based on safety data from a randomized trial including 414 subjects with estimated GFR 
of 20-60 mL/min/1.73 m2 comparing sacubitril/valsartan to irbesartan, the exclusion criteria was lowered to allow subjects with an estimated GFR of 20 mL/min/1.73 m2 and higher (Haynes R et al 2018)[COMPANY_003]
[COMPANY_001] Page 21
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
Amendment 2: Significant changes from Protocol Version 01 include:
!Covid-19 exclusion criteria language was added
!Allowance for virtual visits at visits 10, 12, 14, and 16, based on patient stability and 
Investigator discretion
!Updated dosing table 6-5 and Section 6.6.2 to initiate study drug at Dose Level 1 if the 
patient’s estimated GFR is <30mL/min/1.73 m2
A copy of this amended protocol will be sent to the Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) and Health Authorities.
The changes described in this amendment require IRB/IEC approval prior to implementation. 
In addition, since the changes herein do affect the informed consent, sites will be required to update and submit for approval a revised informed consent that takes into account the changes.
Amendment 3: Significant changes from Protocol Version 02 include:
 
 
Amendment 4: Significant changes from Protocol Version 03 include: 
!Inclusion of patients with a WHF event (HFpEF decompensation), defined as a 
hospi[INVESTIGATOR_059], emergency department (ED) visit or out-of-hospi[INVESTIGATOR_669374], all requiring IV diuretics
!Qualifying age changed from >=40 to >=18 years old
!Sample size reduced to 450 patients (from 800 patients)
!Key secondary endpoints (the win ratio endpoint and the triple composite endpoint) were 
moved to a secondary position, with the trial power shifting to the NTproBNP primary 
endpoint
!Exclusion 2 modified to allow prior Entresto usage if >60 days
!Exclusion 6 modified to allow PI [INVESTIGATOR_669394]-like symptoms 
(COPD, Hgb, Obesity) 
!Altered the visit schedule (see Section 8 ) reducing total visits from 15 to 10 visits
!Updated language for contraception (exclusion 22) 
1.[ADDRESS_904067] of sacubitril/valsartan vs. valsartan on changes 
in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF 
decompensation) who have been stabilized and initiated at the time of or within [ADDRESS_904068] decompensation.P
PD
[COMPANY_001] Page 22
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints 
Objective(s) Endpoint(s)
Primary  Objective(s) Endpoint(s) for primary objective(s) 
To demonstrate the effect of 
sacubitril/valsartan vs. valsartan on 
time-averaged proportional change 
in NT- proBNP from baseline to 
weeks 4 and 8  in HFpEF patients 
with a WHF event (HFpEF 
decompensation) who have been 
stabilized for and initiated at the 
time of or within [ADDRESS_904069]-
decompensationThe time averaged proportional change in NT -
proBNP from Baseline to Weeks 4 and 8.
Secondary  Objective(s) Endpoint(s) for secondary  objective(s)
To determine the effect of 
sacubitril/valsartan vs. valsartan on 
the composite hierarchical 
outcome consisti ng of: a) time to 
CV death, b) total HF 
hospi[INVESTIGATOR_059] s, c) total urgent HF 
visits, and d) time- averaged 
proportional change in NT -
proBNP (from baseli ne to weeks 4 
and 8 ) using win ratio 
methodologyThe composite hierarchical outcome consisting 
of: a) time to CV death, b) number and times 
of HF hospi[INVESTIGATOR_663322] -up, c) 
number and times of urgent HF visits during 
follow -up, and d) time averaged proportional 
change in NT -proBNP ( from baseline to 
Weeks 4 and 8 )
To assess the effect of 
sacubitril/valsartan vs. valsartan on 
total composite events based on 
CV death, HF hospi[INVESTIGATOR_602], and 
urgent HF v isitsThe cumulative number of recurren t composite 
events overtime, i.e., the total number of 
composite events of HF hospi[INVESTIGATOR_602], 
urgent HF visits, and CV death . 
To assess the effect of 
sacubitril/valsartan vs. valsartan on 
the incidences of a composite 
endpoint of worsening renal 
functi on (renal death, reaching 
ESRD, or decline in eGFR >/= 
50%)The incidences of a composite endpoint of 
worsening renal function, defined as:
orenal death
oreaching end-stage renal disease 
(ESRD)
o≥ 50% decline in estimated glomerular 
filtration rate (eGFR) relative to 
baseline
To assess the effect of 
sacubitril/valsartan vs. valsartan on Proportional change in NT- proBNP from 
baseline to Week 8

[COMPANY_001] Page 23
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
Objective(s) Endpoint(s)
change in NT-proBNP from 
baseline to Week 8 
!To assess the effect of 
sacubitril/valsartan vs. valsartan on change from baseline in hs-Troponin (high sensitivity) at 
Weeks 4 and 8!Proportional change from baseline in hs-
Troponin (high sensitivity) at Weeks 4 and 8
!To assess the effect of 
sacubitril/valsartan vs. valsartan on tolerability and the incidence of adverse events of special interest during treatment!Dosing levels and discontinuations
!Incidence of symptomatic hypotension during
treatment 
!!Incidence of hyperkalemia (potassium >5.5 
mEq/L)  
!Incidence of angioedema 
!Incidence of worsening renal function, defined 
as an increase in serum creatinine of ≥0.5mg/dl and worsening of the eGFR by [CONTACT_12697] 25% 
[COMPANY_003]
P
[COMPANY_001] Page 24
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
3 Study design
Figure 3-1 Study Design
This study will use a randomized, double-blind, double-dummy, active-controlled, 
parallelgroup design. Eligible patients will be randomized either during hospi[INVESTIGATOR_272], orwithin 30 days of, a WHF event (HFpEF decompensation). A WHF event (HFpEF decompensation) is defined as a hospi[INVESTIGATOR_059], emergency department (ED) visit or out-of-hospi[INVESTIGATOR_669374], all requiring IV diuretics.
[COMPANY_003]
[COMPANY_001] Page 25
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Randomized patients will have been hemod ynamically stabilized defined in this study  as: 
SBP ≥100mmHg for the preceding 6 hours prior to randomization; no sy mptomatic 
hypotension 
No increase (intensification) in IVdiuretic dose within last 6 hours prior to randomization
No IVinotropic drugs for 24 hours prior to randomizatio n
No IVvasodilators including nitrates within last 6 hours prior to randomization
All patients will need to meet all other inclusion and none of the exclusion criteria.  
Patients will be randomized 1:1 to sacubitril/valsartan or valsartan. Initial dose at randomization 
will be determined based on the patient’s previous dose of or lack of ACEi/ARB immediately 
prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation
randomization.
Patients currently  or recently  taking ACEi: In order to provide for a necessary 36 -hour washout 
of prior ACEi treatment before receiving sacubitril/valsartan, eligible patients will be 
randomized no earlier than [ADDRESS_904070] patient randomized after the amendment is 
approximately  20 months; the anticipated minimum follow -up would be for 8 weeks.  
4 Rationale
4.1 Rationale for study  design
Hospi[INVESTIGATOR_669395]-hospi[INVESTIGATOR_669396]. This increased risk justifies intervention with novel treatment strategies 
initiated prior to hospi[INVESTIGATOR_146451].
The PARADIGM -HF and PARAMOUNT trials demonstrated reductions in NT-proBNP 
compared to the comparator enalapril and valsartan, respectively , in patients with chronic 
reduced ejection fraction and preserved ejection fraction heart failure ( McMurray  et al 2014; 
Packer et al 2015 ; Solomon et al 2012 ).
PARAGON -HF demonstrated 
increased risk of events in HFpEF patients who were recentl y 
hospi[INVESTIGATOR_669397]/valsartan appeared greater in those patients 
hospi[INVESTIGATOR_22318] 30 days of screening, compared to those hospi[INVESTIGATOR_669398] 30 days 
or never previousl y hospi[INVESTIGATOR_057] (Vaduganathan et al 2019). 
The PI[INVESTIGATOR_15597] -HF trial evaluated the effect of in-hospi[INVESTIGATOR_146444]/valsartan vs. 
enalapril in patients with HFrEF who had been stabilized during hospi[INVESTIGATOR_320013]. 
PI[INVESTIGATOR_15597] -HF demonstrated greater reduction in NT-proBNP with sacubitril/valsartan vs. 
enalapril in time -averaged proportional change in NT -proBNP from baseline to weeks 4 and 8 

[COMPANY_001] Page 26
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
(percent change, -46.7% vs.-25.3%;ratio ofchange with sacubitril/valsartan vs.enalapril 0.71 
[0.63 –0.81], p<0.001) and a decrease in the pre-specified, exploratory , serious clinical 
composite outcome of death, re-hospi[INVESTIGATOR_669399], LVAD implantation, orlisting 
for cardiac transplant (Velazquez et al2018).   This current trial(PARAGLIDE- HF)willbuild
upon thedata generated through thePI[INVESTIGATOR_15597] -HFtrial by [CONTACT_669439] y study ing patients with 
HFpEF and ADHF .  PAR AGLIDE -HF will have a similar primary end -point of NT-proBNP to 
PI[INVESTIGATOR_15597] -HF, but will also include patients randomization during a WHF event (requiring IV 
diuretics) and within thirty  days post
-decompensation .  The duration of PARAGLIDE -HF will 
be up to 20 months to account for accrual of the secondary  outcome events .
The need for a 36-hour wash -out period is required per the FDA approved USPI  [INVESTIGATOR_146477] a potential for increased risk for angioedema in patients who receive both an ACE 
inhib itor and the combination of sacubitril/valsartan. The requirement to stop the ARB is 
because there is an ARB contained within sacubitril/valsartan combination.
4.2 Rationale for dose/regimen and duration of treatment
Sacubitril/valsartan 97/103 mg BID was sele cted as the target dose. This is the USPI [INVESTIGATOR_669400]/valsartan inpatients with HFrEF andisthetarget dose studied in the 
phase III PARAGON -HF trial in patients with HFpEF (Solomon et al 2019). This dose of 
sacubitril/valsartan delivers similar exposures
of valsartan asDiovan 160mgBID, themaximal 
approved Diovan dose for heart failure and the dose recommended in international guidelines 
for the treatment of heart failure. In addition, biomarker an alysis (increase in ANP and cGMP) 
indicates  that  this  sacubitril  dose  delivers   approximately   90%  of  its  maximal neutral 
endopeptidase (NEP) inhibition Dosing with 97/103 mgtwice dailyis to ensure sustained NEP 
inhibition over 24 hours, which is thought to be critical for patients with heart failure. Both the 
PI[INVESTIGATOR_15597] -HF and TRANSI TION studies demonstrated that patients with heart failure with 
reduced ejection fraction could be safel y initiated on sacubitril/valsartan in the hospi[INVESTIGATOR_669401] ( Velazquez et al 2018 , Wachter et al 2018 ). 
In PARAGON -HF, HFpEF patients were followed for a median time of 35 months 
(interquartile range, 30 to 41) with no new safety signal seen, and consistent safet y to 
PARADIGM -HF.  In this study , the duration of treatment will be from 8 weeks (minimum) to 
approximately  20 months
(maximum). The longer duration of follow -up allows for more events 
to occur, facilitating more accurat e assessment of the clinical outcome secondary  endpoints..
4.3 Rationale for choice of comparator
To date, there is no evidence- based, guideline -recommended, pharmacologic therapy  for 
HFpEF patients that has been proven to reduce morbidity  and mortality  (Yancy  et al 2013). 
Valsartan is being given to treat the comorbidities that are prevalent in HFpEF, such as HTN, 
DM, and coronary  artery disease where there is an indication for RAS blocking therap y 
(McMurray  et al 2012 ). For the same reason, 
background ACEIs or ARBs were permitted in 
other outcomes studies inHFpEF fortreating comorbidities, including TOPCAT, where aRAS 
blocker was used in 85% of patients at baseline ( Desai et al 2011).

[COMPANY_001] Page 27
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Valsartan waschosen astheRAS blocker comparator because it isacommonly prescribed ARB 
and the target dose of sacubitril/valsartan (LCZ696) delivers systemic exposure similar to the 
target dose of valsartan for heart failure. It was also the comparator used in both the 
PARAMOUNT study aswell asinthePARAGON -HFstudy inpatients with HFpEF.
Aplacebo comparator isnotconsidered appropriate inthistrial, asthecomorbidities commonly  
present in HFpEF patients require RAS inhibition (i.e., ACEI  or ARB). RAS inhibition should 
not be used concomitantly  with LCZ696 due to the potential increased risk of angioedema 
(ACEI), andbecause LCZ696 alread yprovides AT1 blockade (ARB).
4.4 Purpose and timing of interi m analy ses/design adaptations
There is no planned interim analy sis for efficacy  in the study . See Section 12.[ADDRESS_904071] of their background 
cardiovascular 
(CV) medications. The risk to patients in this trial will be minimized by [CONTACT_669440].  A D ata Monitoring Committee (DMC) will 
also monitor the study  for all safety  considerations, since this population represents a patient 
population who are being initiated on study drug during the same hospi[INVESTIGATOR_669402]. 
Wom en of child bearing potential and sexually  active males must be informed that taking the 
study  treatment may  involve unknown risks to the fetus if pregnancy  were to occur during the 
study , and agree that in order to participate in the study the y must adher e to the highl y effective 
contraception requirements outlined in the exclusion criteria. If there is any question that the 
patient will not reliably  comply , they  should not be entered or continue in the study .
Participating patients will benefit from careful monitoring and follow -up during the entire study 
duration regardless of whether they  are receiving study  medication.
[ADDRESS_904072] of male and female patients, ≥ 18years of age, current ly 
hospi[INVESTIGATOR_669376] 30 daysof a WHF event (HFpEF decompensation).  A WHF event 
(HFpEF decompensation) is defined as a hospi[INVESTIGATOR_059], emergency  department (ED) visit or 
out-of- hospi[INVESTIGATOR_669374] , allrequiring IV diuretics. A total of approximately 450patients 

[COMPANY_001] Page 28
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
will be randomized to sacubitril/valsartan or valsartan in a 1:1 ratio at approximately  130 centers
in the [LOCATION_002] and Canada
Patients are defined as , (1) those randomized and completing the trial 
according to the Or iginal 
Protocol V ersion 00, and (2) those randomized ( or eligible and re -consented Original protocol 
patients) based on Amendment 1, which will be pooled for the final analy sis (including a 
sensitivity  anal ysis to ensure consistency  (see Section 12.4.3 ).
A total of approximately  450 patients will be randomized to sacubitril/valsartan or valsartan in 
a 1:[ADDRESS_904073] been hemod ynamically stabilized defined in this study  as: 
SBP 
≥100mmHg for the preceding 6 hours prior to randomization; no sy mptomatic 
hypotension 
No increase (intensification) in IVdiuretic dose within last 6 hours prior to randomi zation
No IVinotropic drugs for 24 hours prior to randomization
No IVvasodilators including nitrates within last [ADDRESS_904074] meet allof the following criteria:
1. Signed informed consent must be obtained prior to participation in the study
2.Patients ≥18years of age, male or female
3. Current hospi[INVESTIGATOR_669403] (HFpEF de compensation), or within 30 day s of 
discharge following a WHF event (defined as hospi[INVESTIGATOR_059], emergency  department 
(ED) visit or out -of-hospi[INVESTIGATOR_669374] , allrequiring IV diuretics). Patients with a 
diagnosis of acute heart failure had to have s ymptoms and signs of fluid overload (i.e. 
jugular venous distention, edema or rales on auscultation or pulmonary  congestion on 
chest x -ray). Eligible patients will be randomized after IV diuresis for HFpEF is given 
(and no earlier than [ADDRESS_904075] ACEi dose if applicable) and within [ADDRESS_904076]-decompensation after presentation with acute HFpEF decompensation and meeting 
the following definitions of hemod ynamic stability:
Randomized patients will have been hemod ynamically stable defined in thi s study as: 
a.SBP≥100mmHg for the preceding 6 hours prior to randomization; no sy mptomatic 
hypotension 
b. No increase (intensification) in IVdiuretic dose within last [ADDRESS_904077] recent LVEF >40% (within past 3 months)

[COMPANY_001] Page 29
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
5.Elevated NT -proBNP or BNP at the time of acute HFpEF decompensation or post-
decompensation screening (and within [ADDRESS_904078] -decompensation randomization, 
if applicable): Patients not in AF at the time of biomarker assessment: NT -proBNP ≥ 
500pg/mL or BNP ≥ 150 pg/mL ; patients in AF at the time of biomarker assessment: NT -
proBNP ≥ 1000pg/mL  or BNP ≥ 300 pg/mL
a.Patient s recruited in -hospi[INVESTIGATOR_669404] -hospi[INVESTIGATOR_669379] -proBNP or BNP value.
b.Patients enrolled post-decompensation can be randomized based on their NT -proBNP 
or BNP value in the following way :
if enrolling in post-decompensation setting then need eligible screening/local NT -
proBNP/BNP within [ADDRESS_904079] value could be from 
recent hospi[INVESTIGATOR_669380] 72 hours or 
would require (re)drawing NT -proBNP or BNP labs in post -decompensation
setting if the lab value is not alread y available within the last [ADDRESS_904080] reduced the 
LVEF (i.e., MI, CABG), unless an echo measurement was performed after the event 
confirming the LVEF to be >40%
2.Entresto™ (sacubitril/valsartan) usage within the past 
60days
3.eGFR < 20ml/min/1.73 m2 as measured by [CONTACT_669441] (MDRD) formula at most recent assessment prior to randomization and within 24 
hours prior to inpatient randomization or 72 hours prior to outpatient randomiz ation
4.Serum potassium > 5.2 mEq/L  at most recent assessment prior to randomization and 
within 24 hours prior to inpatient randomization or 72 hours prior to outpatient 
randomization
5.Acute coronary  syndrome, stroke, transient ischemic attack; cardiac, carot id or other 
major CV surgery ; percutaneous coronary  intervention (PCI ) or carotid angioplast y, 
within 30 day s prior to randomization
6. Probable alternative diagnoses that in the opi[INVESTIGATOR_669405]’s HF s ymptoms (i.e. dy spnea, fatigue) such as significant pulmonary disease 
(including primary  pulmonary  HTN), anemia or obesity . 
7.Isolated right HF in the absence of left -sided structural heart disease
8.History  of hypersensitivity  (i.e. including angioedema), known or suspected
contraindications, or intolerance to an y of the study drugs including ARNIs (i.e. 
sacubitril/valsartan), and/or ARBs

[COMPANY_001] Page 30
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
9.Patients with a known history  of angioedema due to any  etiology
10.Patients with a history  of heart transplant or LVAD, currently  on the transplant list, or 
with planned intent to implant LVAD or CRT device within the initial three months of 
enrollment during the trial 
11.A cardiac or non- cardiac medical condition other than HF with an estimated life 
expectancy  of < 6months
12.Known pericardial con striction, genetic hy pertrophic cardiom yopath y, or infiltrative 
cardiom yopath y including suspected or confirmed amy loid heart disease (amyloidosis)
13.Life-threatening or uncontrolled dy srhythmia, including s ymptomatic or sustained 
ventricular tach ycardia and atrial fibrillation or flutter with a resting ventricular rate >110 
bpm
14.Clinically  significant congenital heart disease felt to be the cause of the patient’s 
symptoms and signs of HF
15.Coronary  or carotid artery  disease or valvular heart disease likely  to require surgical or 
percutaneous intervention within the duration of the trial 
16.Any surgical or medical condition, which in the opi[INVESTIGATOR_871], may  place the 
patient at higher risk from his/her participation in the study , or is likel y to preven t the 
patient from compl ying with the requirements of the study  or completing the study
17.Known hepatic impairment (as evidenced by [CONTACT_146499] > 3 mg/dL, or increased 
ammonia levels, if performed), or history of cirrhosis with evidence of portal hy perte nsion 
such as varices
18.Participation in any  other clinical trial involving investigational agents or devices within 
the past [ADDRESS_904081] COVI D19 infection with persistent sy mptom burden suspected due to COVID19
Persistent sy mptoms may include, but are not limited to, continued cough, breathing 
difficulty ,muscle/joint aches, and gastrointestinal sy mptoms from the time of 
COVID19 infection onward.   
21.Pregnant or nursing (lactating) women, where preg nancy  is defined as the state of a 
female after conception and until the termination of gestation, confirmed b y a positive 
hCG laboratory  test.
22.Women of child
-bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing of investigational drug and for 7 day s off of study  drug. Highly  effective 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient. Peri odic abstinence (e.g., calendar, ovulation, sy mptothermal, post- ovulation
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without
hysterectom y) or tubal ligation at least six weeks before taking study  treatment. I n 
case of oophorectom y alone, only  when the reproductive status of the woman has been 
confirmed b y follow- up hormone level assessment

[COMPANY_001] Page 31
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Male sterilization (at least 6 months prior to Visit 1). For female patien ts on the study , 
the vasectomized male partner should be the sole partner for that patient
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem
(IUS) or other forms of hormonal contraception that have comparable efficacy  (failure 
rate <1%), for example hormone vaginal ring or transdermal hormone contraception
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_904082] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor symptoms) or have had surgical bilateral oophorectom y (with 
or without hy sterectom y) or tubal ligation at least six weeks ago. In the case of oophorectomy 
alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6492] -up 
hormone level assessment is she considered not of child bearing potential. 
In case local regulations deviate from the contraception methods listed above, local regulations 
apply  and w ill be described in the I CF.
[ADDRESS_904083] eight (8) weeks of follow -up in accordance to the protocol.
[COMPANY_001] will supply  the investigators with all study medications required for the course of the 
study . Patients will be provided with study drug corresponding to their assigned treatment arm 
and dose level, sufficient to last until the next scheduled visi t.
This study  is designed as a double -blind, double -dummy  trial to ensure the blinding during the 
entire course of the study .  To maintain the blinding, patients will be required to take their 
assigned active treatment tablet along with placebo matching the opposite treatment twice daily .
Both sacubitril/valsartan and valsartan and their matching placebos will be packaged and 
labeled by [CONTACT_669442], and will be dispensed by  [CONTACT_7536].
Table 6-1 Investigational and control drug
Investigational/ 
Control Drug
(Name [CONTACT_131377])Pharmaceutical 
Dosage FormRoute of 
AdministrationSupply 
TypeSponsor 
(global or 
local)
Sacubitril/valsartan 
24/26 mg BIDTablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 

[COMPANY_001] Page 32
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Sacubitril/valsartan 
49/51 mg BIDTablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Sacubitril/valsartan 
97/103 mg BIDTablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Sacubitril/valsartan 
matching p laceboTablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global )
Valsartan 40mg BID Tablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Valsartan 80mg BID Tablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Valsartan 160mg BID Tablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Valsartan matching 
placeboTablet Oral use Double Blind 
supply; 
bottlesSponsor 
(global) 
Table 6-2 Treatment Dose Levels
Dose Level Sacubitril/valsartan Valsartan
1 24/26 mg [50mg] BID 40 mg BID
2 49/51 mg [100mg] BID 80 mg BID
3 97/103 mg [200 mg] BID 160 mg BID
Each participating hospi[INVESTIGATOR_669406]’s initial supply  of study 
medication. Bottles will be numbered and assigned via an Interactive Response Technology 
(IRT).
Sacubitril/valsartan dose or valsartan dose levels may  be increased to the targeted desired dose 
of97/103 mg twice dail y or valsartan
160 BID on an every  2-week basis or earlier if based on 
clinical need and investigator judgment
.  Every  effort should be made to titrate to and maintain 
patients on the target dose level, as tolerated b y the patient.
Patients not tolerating the target dose ofsacubitril/valsartan 97/103 mg BID or valsartan
160 
mg BID will be titrated down to the lower dose level (including active medication and matching 
placebos), at the investigator’s discretion, based on the defined safet y and tolerability  criteria. 
Per the guidance in Section 6.4.1 , every  attempt should be made to uptitrate again is the patien t’s 
status allows.
All study  sites will be provided with a Treatment Manual describing the treatment packaging 
and treatment instructions.

[COMPANY_001] Page 33
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
6.1.1 Treatment arms/group
Patient s will be randomized in a 1:1 ratio to receive treatment with either sacubitril/valsartan or 
valsartan .  
6.1.[ADDRESS_904084] patient randomized will be followed for a minimum of 8 weeks . Patient s may be 
discontinued from treatment earlier due to unacceptable toxicity , disease progression and/or if 
treatment is discontinued at the discretion of the investigator or the patient.  Every  attempt 
should be made to maintain patients on the target study  drug dose level for as long as possible 
throughout the stud y.  
6.1.[ADDRESS_904085] the patient to notify  the study  site about any new medications 
he/she tak
es after the patient was enrolled in the study . All medications, procedures and 
significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered 
after the 
patient was enrolled into the study  must be recorded on the approp riate Case Report 
Forms.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a patient or allowing a new medi cation to be started. If the patient is alread y 
enrolled, contact [CONTACT_669443] .
[IP_ADDRESS] Permitted concomitant therapy  requiring caution and/or action
Other heart failure and cardiovascular medicati on
If a patient’s condition warrants any change in concomitant heart failure or cardiovascular 
medications, changes may be made at the investigator’s discretion.
Oral diuretics may be used and may  be adjusted throughout the study  duration at the discretion
of the investigator.
Medications known to raise potassium levels
Potassium sparing diuretics, potassium supplements, aldosterone antagonists, and any other 
medications known to raise potassium levels should be used with caution while the patient is 
receiv ing study  medication due to the increased possibility  of hyperkalemia. Potassium levels 
should be monitored regularly  especially  in those who are receiving these medications.
Concomitant administration of renin inhibitors, such as aliskiren, is prohibited.
Phosphodiesterase -5 (PDE -5) inhibitors
PDE -5 inhibitors should be used with caution while the patient is receiving study  medication 
due to the increased possibility  of occurrence of hy potension.

[COMPANY_001] Page 34
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
6.1.[ADDRESS_904086] be stopped for ≥[ADDRESS_904087]
be stopped prior to re -initiation of study drug
Aliskiren ( in patient s with 
concurrent diabetes or those 
with renal impairment [eGFR 
<60 mL/min/1.73 m ²])Duration of 
studyDiscontinue study drug. The open label renin
inhibitor must be stopped prior to re -initiation of
study drug
Nesiritide and intravenous 
nitratesDuration of 
studyDo not randomize. If hospi[INVESTIGATOR_057], either interrupt or 
discontinue study treatment. Concomitant 
administration of sacubitril/valsartan with n esiritide 
and intravenous nitrates ha snot been studied. Oral, 
topi[INVESTIGATOR_669407].
Bile acid sequestering 
agents (such as 
cholesty ramine or colestipol)Duration of 
studySwitch to alternate agent to avoid interference with 
study drug absorption. If use of alternate agent is not 
appropriate, do not randomize or discontinue study 
drug trea tment.
ACEIs and A RBs
Patients’ pre -study  ACEIs/ARBs will be replaced with the study  medication.
The concomitant use of open label ACEI s or ARBs is strictly  prohibited while the patient is 
receiving study  medication. If the investigator believes that addition of an ACEI or ARB is 
necessary , then stud y drug must be discontinued. Study medication should be stopped [ADDRESS_904088], 
consideration should be given to adding this therapy  rather than an ACEI or and ARB, while 
monitoring renal function.
Nesiritide and intravenous nitrates
The concomitant admission of sacubitril/valsartan with nesiritide and intravenous nitrates has 
not been studied. Concomitant use of nesiritide will not be permitted during the stud y.
Other medications
Bile acid sequestering agents such as cholesty ramine or colestipol are prohibited to avoid 
interfere nce with study  drug absorption.

[COMPANY_001] Page 35
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
6.1.[ADDRESS_904089] the option to discontinue patient s from study 
treatment if they develop signs and symptoms of worsening heart failure for which the 
investigator would like to administer appropriate therapy .
Appropriate adjustments, intensifications, or additions to concomitant medications 
should be considered before deciding to withdraw the patient from study  treatment.
Patient s CANNOT receive ACEIs and/or ARBs during the study. These 
medications can ONLY be administered if the investigator believes that the 
patient needs to be 
withdrawn from study treatment so that they may be treated 
with these therapi[INVESTIGATOR_669408].
If the investigator has not made the decision to permanently discontinue study  
treatment , then the pat ient can resume study  treatment as long as the 36
-hours ACEI
washout was observed.
A 36 -hour wash -out period is required if the investigator chooses to withdraw 
the patient   from study treatment and switch toACEI due to symptoms of 
worsening heart failure.
Use of rescue medication must be recorded on the appropriate Concomitant 
Medications eCRF.
Investigators will use clinical judgment to determine if patient ’s condition requires closer 
monitoring. Unscheduled visits are permitted as needed.
6.2 Patient numbering, treatment a ssignment, randomization
6.2.1 Patient numbering
Each patient is uniquely identified in the study  by a Patient Number (
Patient No.), that is 
assigned when the patient is first enrolled for screening and is retained as the primary identifier 
for the patient throughout his/her entire participation in the trial. The Patient No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential 
patient number suffixed to it, so that each patient is numbered uniquely  across the entire 
database. Upon signing the informed consent form, the patient is assigned to the next sequential 
Patient No. available by [CONTACT_093]. The investigator or his/her staff will contact [CONTACT_669444]. The site will enter this 
number on the electronic case report form (eCRF) in the electronic data capture system (EDC).   
6.2.2 Treatment assignment, randomization
Atrandomization visit, all eligible patient s will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The investigator or his/her delegate will contact 
[CONTACT_286774]/exclusion criteria. The IRT 
will assign a randomization number to the patient , which will be used to link the patient to a 
treatment arm and will specify  a unique medication number for the first package of study 
treatment to be d ispensed to the patient .

[COMPANY_001] Page 36
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patient s and investigator staff. A patient
randomization list will be produced by [CONTACT_6609] a validated system that automates 
the random assignment of patient numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medicatio n list will be produced by [CONTACT_669445]  (GCS) using a validated sy stem that automates the random assignment 
of medication numbers to bottles containing the study  treatment.
The randomization scheme for patients will be reviewed and approved by  [CONTACT_5343]. 
Initial dose at randomization will be determined based on the patient’s previous dose of or lack 
ofACEi/ARB immediately  prior to current WHF event (HFpEF decompensation) , or at the time 
of post-decompensation randomization.  Dose adjustments to lower dose levels may be made 
at any time at both scheduled and unscheduled visit only if clinically  indicated for blood 
pressure control or tolerability  reasons. Dose adjustments to increase dose levels may  be made 
at any time at both scheduled and unscheduled visits based on clinical need or investigator 
judgment .
Subsequent supplies of study  drug will be assigned in the following manner. The investigator 
or his or her delegate will call the IRT and provide the patie nt’s number. The IRT will ask the 
caller whether there is a change in the dose level of the study  drug. If the caller indicates that 
there is no change in the dose level, the I RT will provide the unique medication numbers of the 
study  drug with the same dose level that was dispensed at the previous dispensing. If the caller 
indicates that the dose level has changed since the last dispensing, the IRT will ask the caller 
which dose level should be dispensed.  The caller will enter the dose level to dispense or whether 
no study  drug should be dispensed (in case of study  drug withdrawal). If applicable, the IRT 
will provide the unique medication numbers for the study  drug supplies that should be dispensed 
at the new dose level. 
6.[ADDRESS_904090] igator staff, persons performing the assessments, and Clinical Trial Team ( CTT )
will remain blind to the identity of the treatment from the time of randomization until database 
lock, using the following methods: (1) Randomization data are kept strictly confidential until 
the time of unblinding, and will not be accessible by [CONTACT_669446], members of the Data 
Monitoring Committee (DMC) and the independent biostatisti cian and programmer assigned to 
the DMC .  (2) The identity  of the treatments will be concealed by [CONTACT_669447], labeling, schedule of administration, appearance, taste and 
odor.
Unblinding may be considere d in the case of patient emergencies.  It is highl y recommended 
that the investigator/site coordinator contact [CONTACT_669448], as most often, study  treatment discontinuation and knowledge of the 
possible treatment assignments are sufficient to treat a study  person who presents with an 

[COMPANY_001] Page 37
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
emergency  condition.  Full u nblinding will occur at the conclusion of the study , after database 
lock.
6.4 Dose modification
6.4.1 Dose modifications
For patient s who do not tolerate the protocol - specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow patient s to continue 
the study  treatment.
Deviations to mandatory  dose interruptions and/or reductions are not allowed. Permanent 
treatment discontinuation is mandatory  for specific events listed in Section 9.1.1.
These dose changes must be recorded on the appropriate case report form ( CRF )
.
Every  attempt should be made to maintain patients on the target study  drug dose level for as 
long as possible throughout the study .  If, however, in the opi[INVESTIGATOR_871], a patient
is unable to tolerate the protocol -specified target dose, the investigator should consider whether 
dose adjustments of concomitant medications may rectify  the situation before reducing the dose 
of study  treatment. If adjustment of the concomitant medications is not possible or does not 
alleviate the side effects of concern, the investigator may down-titrate the dose of the study  drug 
to the previous dose level. If needed, the study  drug may  be stopped completely , if this occurs, 
the patient should return to the clinic as soon as possible, after discontinuation of study  drug, 
for an end of study  visit.  Patient s may restart their current dose of study drug following an 
interruption of treatment, based on investigator judgment.  
Study  drug dose level adjustments should be mainly  based on overall safety  and tolerability 
with special focus on:
Hyperkalemia
Symptomatic hy potension
Clinically  significant decrease in eGFR/increase in serum creatinine (defined as a 
serum creatinine of ≥0.5mg/dl with at least a 25% d ecrease in eGFR)
Angioedema
These changes must be recorded on the appropriate CRF. E very attempt should be made to 
titrate to and maintain patient s on target study  drug Dose Level 3 for as long as possible 
throughout the study . If, however, in the opi[INVESTIGATOR_871], a patient is unable to 
tolerate the protocol -specified target dose, the inve stigator will manage the patient’s treatment 
according to the below guidelines:
Steps:
1. Adjust Concomitant Medications
Dose adjustments/elimination of concomitant medications may  remedy  the situation 
before reducing the dose of study  treatment. If adjustment of the concomitant 
medications is not possible or does not alleviate the side effects of concern, THEN;

[COMPANY_001] Page 38
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
2.Adjust Study Treatment Dose Level
Down -titrate study  treatment to the previous dose level. The patient may continue 
receiving the lower dose level for a recommended period of 1 to a maximum of 4 
weeks.
A re-challenge to titrate back up to the target dose level should be attempted at 2 
weeks, or when patient is deemed stable. THEN:
3. Further Adjust Study Treatment Dose Level
If tolerability  issues are not alleviated despi[INVESTIGATOR_146487]- titration by  [CONTACT_30560], the 
investigator may  down -titrate further to the next lower study  treatment dose level. The 
patient may continue receiving the lower dose level for a recommended period of 1 to 
a maximum of 4 we eks. See Step 5.
Again, once stable, the patient should be re -challenged with up -titration to the next 
higher dose level in an attempt to gradually  bring the patient back to the target study  
treatment dose level (Dose Level 3).
The investigator may  choose the next dose level for down- or up -titration according to 
his or her clinical judgment.
4.Stoppi[INVESTIGATOR_669409]
If needed, the study treatment may be stopped completely, however, every effort must 
be made to complete an end of study visit and obtain follow up health status 
information and NT- proBNP for any  patient that withdraws from the study . 
5.Study drug restart a fter temporary treatment interruption
Once the investigator considers the patient ’s condition appropriate for receiving the 
study  drug, the investigator should re -start the patient on study  treatment at the most 
appropriate and allowable dose level per his /her medical judgment.
If tolerated, the patient should be titrated up to the next dose level every  1 to 4 weeks, 
as per the investigator’s judgment.
In some instances, Dose Level 1 or 2 could be maintained if the investigator considers 
that the patient ’s condition would not allow any  further up -titration to the target dose 
of study  medication (Dose Level 3). In this case, it would be acceptable to maintain 
the patient at Dose Level 1 or 2, whichever is the higher and tolerated dose level by  
[CONTACT_102] , but reasons for not getting to Dose Level 3 need to be captured in the 
eCRF.
Should the patient not tolerate the re -start study  drug dose level, he/she may  be down -
titrated again (if appropriate) or discontinued from study  treatment.
Patient s re-started on 
the study  drug will retain their original randomization and study 
identification numbers.
The IRT must be contact[CONTACT_146526] ’s study  treatment dose level, 
including in cases of temporary  and permanent withdrawal or re -start of the study  drug, and to 
obtain the medication numbers of the study  drug supplies required for the new study  treatment 
dose level. All dose changes and interruptions must also be recorded on the appropriate eCRF.

[COMPANY_001] Page 39
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Study  visits should occur as close as possibl e to the pre-defined visit and time schedule 
described inTable 8-1. The timeframe between the regular visits should be maintained as 
scheduled, irrespective of the number of unscheduled visits tha
t may  be performed in between, 
or dose interruptions that may  occur.
In case of pregnancy  discovered during the study , the patient should be instructed to stop taking 
the study  drug immediately . 
6.4.2 Follow -up for angioedema
Angioedema is a ty pe of abrupt swelling th
at occurs under the skin and/or mucous membranes 
and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, 
including the genitalia and intestines.  Severe cases may be associated with airway  compromise.  
It is important that the investigator pays special attention to any swelling or edema that may 
resemble angioedema or angioedema -like events that may be reported by [CONTACT_1962].  If such an 
event occurs, the investigator will complete a Questionnaire for an Angioedema -like Event form 
(provided b y [COMPANY_001]) to summarize the event, its treatment and its ultimate outcome.  
The investigator may be also contact[CONTACT_669449] -like event.  A list of terms that are consid ered ‘angioedema- like’ will be provided 
to sites in a manual.  
Details on the procedures for reporting angioedema events will be provided to investigators in 
a manual.
6.5 Additional treatment guidance
6.5.1 Treatment compliance
Compliance will be assessed by  [CONTACT_330312]/or study  personnel at each visit (including 
during pandemic -related virtual visits, when applicable) using pi[INVESTIGATOR_669410]. This information should be captured in the source document at each 
visit. Patient compliance should be at least 80% .The investigator and/or study  personnel will 
counsel the patient if compliance is below 80%. Study  drug accountability  will also be 
determined b y the site monitor while performing routine site visits and at the co mpletion of the 
study .
Duration of double -blind study  drug exposure will be calculated based upon the start and stop 
dates recorded in the eCRF.
6.5.[ADDRESS_904091] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a patient , he/she must provide the 
requested patient identifying information and confirm the necessit y to break the treatment code 

[COMPANY_001] Page 40
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
for the patient . The investigator will then receive details of the investigational drug treatment 
for the specified patient and a fax or email confirming this information. The system will 
automatically  inform the [COMPANY_001] monitor for the site and the Clinical Trial L eadthat the code
has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
patient number
In addition, oral and written information to the patient must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
6.6 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.  
A unique medication number is printed on the study  medication label.  Investigator staff will 
identify  the study  medication bottles to dispense to the patient by [CONTACT_18608](s). The study medication has a 2- part label (base plus tear -off 
label), immediatel y before dispensing the medication bottle to the patient , site personnel will 
detach the out er part of the label from the packaging and affix it to the source document.
During the COVID -19 pandemic that limits or prevents on-site study  visits, delivery  of IP 
directly toaparticipant’s home isgenerall ypermitted intheevent theInvestigator hasdecided 
that an on-site visit by [CONTACT_348178], and that it is in the 
interest oftheparticipant’s health toadminister thestudy treatment even without performing an 
on-sitevisit. Implementation willneed tobediscussed with [COMPANY_001]. Thedispatch ofIPfrom the 
site to the participant’s home remains under the accountability  of the Investigator. Each 
shipment/provisioning will be for a maximum of 4-months supply . In this case, regular phone 
calls or virtual contacts are suggested per Investigator discretion based on patient stability  and 
status 
until the participants canagain visit thesite.
6.6.1 Handling of study treatment and additional treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels and in the Investigator’s Brochure. Clinical supplies are to 
be dispensed only in accordance with the protocol. Technical complaints are to be reported to 
the respective [COMPANY_001] US Quality  Assura nce.

[COMPANY_001] Page 41
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
The investigator must maintain an accurate record of the shipment and dispensing of 
investigational and comparator treatment in a drug accountability  log. Monitoring of dru g 
accountability  will be performed by [CONTACT_669450]. Patients will be asked to return all unused investigational or comparator 
treatment and packaging at the end of the stud y or at the time of discontinuation of treatment. 
At the conclusion of the study , and as appro priate during the course of the study , the investigator 
will return all unused investigational and comparator treatment, packaging, drug labels, and a 
copy  of the completed drug accountability  log according to the instructions provided by 
[CONTACT_669451] a gents.
6.6.2 Instruction for prescribing and taking study treatment
All medication for the duration of the stud y will be provided b y [COMPANY_001]. Eligible patient s will 
be randomized via IRT to either sacubitril/valsartan or valsartan. 
Patients will be provided with sufficient medication to last until the next scheduled visit. In 
order to adequatel y blind the study , patients will be required to take a total of two tablets (one 
tablet from the sacubitril/valsartan / sacubitril/valsartan matching placebo bottle and one tablet 
from the valsartan/valsartan matching placebo bottle ) twice a day  for the duration of the study .
Initial dose at randomization will be determined based on the patient’s previous dose of or lack 
ofACEi/ARB immediately  prior to current WHF event (HFpEF decompensation) , or at the time 
of post-decompensation randomization
. 
For patients who were not being treated with ACEi/ARB at the time of presentation to 
hospi[INVESTIGATOR_307] , or at the time of post-decompensation randomization, the starting dose 
should be dose level 1. 
For patients with an estimated GFR of >20 to <30 mL /min/1.73 m2, regardless of 
ACEi/ARB dose at the time of presentation to hospi[INVESTIGATOR_669411]-decompensation
randomization, should be initiated at dose level 1. 
Those pa tients previously  treated with low dose of ACEi/ARB ( Table 6 - 4)should be 
initiated at dose level 1. 
For patients previo usly treated with high dose ACEi/ARB (Table 6 -4), the starting 
dose is dose level 2. 
Table [ADDRESS_904092]-decompensation randomization.
The target dose for sacubitril/valsartan is 97/103 mgBID and for valsartan is 160 mgBID(dose 
level 3). Every  attempt should be made to titrate to and maintain patients on the target study 
drug dose level for as long as possible throughout the study . However, maximal doses for study 
medication will be determined by  [CONTACT_669452] ’s clinical status. It is 
recommended that patients remain at each dose level during up -titration for 1 to 2 weeks such 
that patients initiated at dose level 1 reach target dose in 2 to 4 weeks and those patients initiated 
at dose level 2 reach target dose in 1 to 2 weeks. In certain circumstances, longer up-titration 
periods may  be required a s deemed necessary  by [CONTACT_093]. 

[COMPANY_001] Page 42
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
If patients cannot tolerate the target dose of stud y medication (dose level 3), down titration to a 
lower dose is allowed (see Section 6.4). Patients should be re-challenged to the target dose of 
study  medication when their condition permits up-titration based on their systolic blood 
pressure (SBP), eGFR, potassium values, and at the investigator ’s discretion. However, patients 
can remain at low doses (level 1 or2), based on their tolerability  and clinical judgment of the 
investigator.
Up titration may be done prior to the week 1 visit at the investigator’s discretion 
i.e., if 
concerned about managing h ypertension. 
Table 6-4 Definition of lo w and high total daily  doses for commonly  used A CEIs 
and A RBs
ACEi/ARB Low RA Sistratum
(total daily dose)High RA Sistratum
(total daily dose)
ACEis
Enalapril ≤ 10 mg > 10 mg
Benazepril ≤ 20 mg > 20 mg
Captopril ≤ 100 mg > 100 mg
Fosinopril ≤ 20 mg > 20 mg
Lisinopril ≤ 10 mg > 10 mg
Moexipril ≤ 7.5 mg > 7.5 mg
Perindopril ≤ 4 mg > 4 m g
Quinapril ≤ 20 mg > 20 mg
Ramipril ≤ 5 mg > 5 m g
Trandolapril ≤ 2 mg > 2 m g
ARBs
Candesartan ≤ 16 mg > 16 mg
Eprosartan ≤ 400 mg > 400 mg
Irbesartan ≤ 150 mg > 150 mg
Losartan ≤ 50 mg > 50 mg
Olmesartan ≤ 10 mg > 10 mg
Telmisartan ≤ 40 mg > 40 mg
Valsartan ≤ 160 mg > [ADDRESS_904093] -decompensation randomization *Starting dose level of study medication
Patie nts not being treated with ACEi/ARB at the time of 
presentation to hospi[INVESTIGATOR_669412]-of-hospi[INVESTIGATOR_669413] 1

[COMPANY_001] Page 43
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Estimated GFR >20 and <30 mL/min/1.73 m2, regardless 
of ACEi/ARB dose at the time of presentation to hospi[INVESTIGATOR_669414]-decom pensation randomizationDose level 1
Low dose ACEi/ARB Dose level 1
High dose ACEi/ARB Dose level 2
* A 36- hour washout of prior ACEi treatment is required before administering sacubitril/valsartan. Eligible patients hospi[INVESTIGATOR_669415] [ADDRESS_904094]-decompensation (with a [ADDRESS_904095] outpatient ACEi dose).
Dose adjustments to lower dose levels may be made at any time at both scheduled and 
unscheduled visits only  if indicated for blood pressure control/tolerability  reasons.
Study  medication should be taken with a glass of water with or without food. If the patient
misses taking an y stud y drug dose, he/she should take it as soon as possible, unless it is almost 
time for the following scheduled dose. In this case, the patient should skip the missed dose and 
return back to his/her regular study  drug administration schedule. 
All bottle s of study  treatment assigned by  [CONTACT_669453] s ystem. 
The investigator should promote compliance by [CONTACT_268290] y as prescribed and by [CONTACT_268291] ’s 
safet y and the validity  of the study . The patient should be instructed to contact [CONTACT_356249]/she is unable to take the stu dy treatment as prescribed for an y reason. 
7 Informed consent procedures
Eligible patient s may  only  be included in the study  after providing (witnessed, where required 
by [CONTACT_6617]), I RB/IEC -approved informed consent.
If applicable, in cases where t he patient 's representative(s) gives consent (if allowed according 
to local requirements), the patient must be informed about the study  to the extent possible given 
his/her understanding. If the patient is capable of doing so, he/she must indicate agreemen t by 
[CONTACT_37249] y signing and dating the written informed consent document.
During the COVID -[ADDRESS_904096] the 
informed consent discussion remotely  (e.g. telephone, videoconference). Guidance issued by 
[CONTACT_348182] y 
documented (e.g. the presence of an impartial witness, sign/dating separat e ICFs by [CONTACT_348183], etc).
For continuity  of trial procedures, the Investigator may continue to conduct the informed 
consent discussion remotely  as described above for the remainder of the trial, or as otherwise 
described b y local regulatory bodies.
Informed consent must be obtained before conducting any study -specific procedures (e.g., all 
of the procedures described in the protocol). The process of obtaining infor med consent must 
be documented in the patient source documents.

[COMPANY_001] Page 44
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
Eligible patients enrolled in the Original Protocol (Version 00) must sign a new informed 
consent form to participate in Amendment 1 (Protocol Version 01).Eligible patients are defined 
as those currently  enrolled in the double -blind treatment period of the Original Protocol at the 
time of each site’s Amendment [ADDRESS_904097] be agreed by  [CONTACT_111908] I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the patient
informed consent and should be discussed with the patient during the study  as needed. Any new 
informatio n regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigator notification or 
an aggregate safet y finding. New information might require an update to t he informed consent 
and then must be discussed with the patient .
Women of childbearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
Male patient s must be informed that if a female partner becomes pregnant while he is enrolled 
in the study , contact [CONTACT_669454] t to collect 
pregnancy  outcome information.
A copy of the approved version of all consent forms must be provided to [COMPANY_001]/sponsor after 
IRB/IEC approval.
8 Visit schedule and assessments
The Assessment Schedule ( Table 8-1 ) lists all of the assessments and when they  are performed
for participants consented to Protocol Amendment V04.  See Section 16.[ADDRESS_904098] 
be supported in the patient’s source documentation.
Patient s should be seen for all visits/assessments as outlined in the assessment sc hedule ( Table 
8-1) or as close to the designated day /time as possible. Missed or rescheduled visits should not 
lead to automatic discontinuation. Patient s who prematurel y discontinue the study  for any 
reason should be scheduled for a visit as soon as possible, at which time all of the assessments 
listed for the 
final visit will be performed. At this final visit, all dispensed investigational 
product should be reconciled, and the adverse event and concomitant medications recorded on 
the CRF.
If the COVID -19 pandemic limits or prevents on-site study  visits, alternative methods of 
providing continuing care may beimplemented. Virtual visits [e.g. phone calls, video 
visits (preferred)] or visits by [CONTACT_6624]/home nursing service to the participant´s home 

[COMPANY_001] Page 45
Amended Protocol Version No. 04(clean)                                                 Protocol No. CLCZ696DUS01
depending on local regulations and capabilities, can replace on-site study  visits, for the duration 
of the pandemic until itissafefortheparticipant tovisit thesiteagain.

[COMPANY_001] Page 46
Amended Protocol Version No. 0 4 (clean ) Protocol No. CLCZ696DUS01
Table 8-1 Assessment Schedule
Period Screening Double -Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study  
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 3 Visit 5 Visit 7 Visit 11 Visit 1 3 Visit 1 5 Visit 1 6 V isit 17
Week
(Day) [Day -30
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 7)4 
(Day 28)8
(Day 56)24
(Day 168)40
(Day 280)56
(Day 392)68 
(Day 476) 84
(Day 588)
Information and 
informed consentS
Inclusion/exclusion 
criteriaX X
Demography / 
Medical historyX
Heart failure and 
CV disease historyX
ECG X
Physical Exam S S S S S S S S
Height X X
Weight X X X X X X X X X X
Waist/hip 
circumferenceX
Vital Signs X X X X X X X X X X
HF signs and 
symptoms and 
NYHA classificationX X X X X X X X X X
Heart failure and 
CV medicationsX X4X X X X X X X X

[COMPANY_001] Page 47
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 3 Visit 5 Visit 7 Visit 11 Visit 13 Visit 15 Visit 16 Visit 17
Week
(Day) [Day -30
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 7)4 
(Day 28)8
(Day 56)24
(Day 168)40
(Day 280)56
(Day 392)68 
(Day 476) 84
(Day 588)
Chemistry labs X X X X X X X X X X
Hematology labs X X X X X X X X
Hemoglobin A1C X X
e G F R X XX X X XXXXX
Urinalysis X
Pregnancy Test2X X X X XXXXX
I R T X XX X X XXXXX
Randomization X
Plasma NT-
proBNP or BNP X5XX X X
hs-Troponin X X X
Drug accountability X X X X X X X X
Dispense study 
treatment XX X X XXXX
Concomitant 
medicationsX XX X X XXXXX[COMPANY_003]
[COMPANY_001] Page 48
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 3 Visit 5 Visit 7 Visit 11 Visit 13 Visit 15 Visit 16 Visit 17
Week
(Day) [Day -30
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 7)4 
(Day 28)8
(Day 56)24
(Day 168)40
(Day 280)56
(Day 392)68 
(Day 476) 84
(Day 588)
Adverse events / 
Serious Adverse eventsX XX X X XXXXX
Angioedema 
assessmentX XX X X XXXXX
Thank You letter X X
Study completion –
randomized treatmentX
Post study 
completion follow upS
6[COMPANY_003]
[COMPANY_001] Page 49
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 3 Visit 5 Visit 7 Visit 11 Visit 13 Visit 15 Visit 16 Visit 17
Week
(Day) [Day -30
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 7)4 
(Day 28)8
(Day 56)24
(Day 168)40
(Day 280)56
(Day 392)68 
(Day 476) 84
(Day 588)
X = assessment to be recorded in the clinical database or received electronically from a vendor
S = assessment to be recorded in the source documentation and in the database
 
2All female patients of childbearing potential will have a serum pregnancy test (hCG) performed at Visit 1 (local lab). A urine pregnancy test will be conducted in the local laboratory for 
remaining visits
4CV medications will be recorded at time of hospi[INVESTIGATOR_2345].
5BNP or NT-proBNP will be assessed at Visit 1 via local laboratory. Only NT-proBNP will be assessed via central laboratory for V isits 2, 3, 5 and 7.
6Health status phone call 4 weeks after study completion.P
[COMPANY_001] Page 50
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
8.1 Screening
A patient who enters screening but is determined not to be eligible will be considered a screen 
failure. The investigator may  consider re -screening the patient at a later time if he/she believes 
that the patient’s condition has changed and they may potentially  be eligible. In this case, a new 
patient number will be allocated to the subject and he/she will need to re-perform all Visit [ADDRESS_904099] provide new written informed consent before 
they are re -screened.
8.1.1 Information to be collected on screening failures
Patient s who sign an informed consent form and subsequently  found to be ineligible prior to 
randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate Case Report Form. The demographic information, informed 
consent, Inclusion/Exclusion pages and Protocol Amendment Log must also be completed for 
screen failure patient s. No other data will be entered into the clinical database for patient s who 
are screen failures, unless the patient experienced a serious adverse event during the screening 
phase (see SAE section for reporting details). If the patient fails to be randomized, the IRT must 
be notified within 2 days of the screen fail that the patient was not randomized.
Patient s who are randomized and fail to start treatment, e.g. patients randomized in error, will 
be considered an early  terminator. The reason for early termination should be recorded on the 
appropriate Case Report Form. 
8.2 Patient demographics/other baseline characteristics
Patient demographic and baseline characteristic data to be collected on all patients include: date 
of birth, age, sex,race, ethnicity  and source of patient referral.  Relevant medical history /current 
medical condition data includes data collected up to the point in which informed consent is 
signed. Where possible, diagnoses and not symptoms, will be recorded. HF medicati ons will be 
recorded in eCRFs separately  from other medications. L ikewise, detailed HF history  and other 
relevant CV medical history  will be recorded on eCRFs separately  from other medical history .
8.3 Efficacy
The efficacy  endpoints are:
Primary  variable:
Time averaged proportional change in NT -proBNP from baseline to Weeks 4 and 8
Secondary  variables:
The composite hierarchical outcome consisti ng of: a) time to CV death , b) number and 
times of HF hospi[INVESTIGATOR_663322] -up, c) number and times of urgent HF visits 
during follow -up, and d) time averaged proportional change in NT -proBNP (from baseline 
to Weeks 4 and 8) using win ratio anal ysis of composite hierarchical outcome

[COMPANY_001] Page 51
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
!The cumulative number of composite events, i.e., the composite events of CV death, total 
HF hospi[INVESTIGATOR_602], and total urgent HF visits for a given subject, over time.
!The incidences of a composite endpoint of worsening renal function (renal death, reaching 
ESRD, or > 50% decline in eGFR relative to baseline)
!Change in NT-proBNP from baseline to Week 8 
!Change from baseline in hs-Troponin (high sensitivity) at Weeks 4 and 8
!Dosing levels, discontinuations, and the incidence of adverse events of special interest 
during treatment
8.3.[ADDRESS_904100] heart sound. NYHA classification will be assessed and documented at each visit.
8.3.2 Estimated glomerular filtration rate (eGFR)
The eGFR to determine eligibility of the patient for screening into the trial will be calculated at 
Visit 1 from the serum creatinine concentration measured at the local laboratory. The eGFR will be further calculated from creatinine concentration measured at Visits 2, 3, 5, 7, 11, 13, 15, and 16 (randomization, Weeks 1, 4, 8, 24, 40, 56, and 68), and end of study (Week 84) at the central laboratory. The eGFR calculation will be based on the Abbreviated Modification of Diet in Renal Disease (MDRD) study equation ( Levey, et al 2007 ).[COMPANY_003]
[COMPANY_001] Page 52
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
8.3.3 Biomarkers
BNP or NT-proBNP will be measured in all patients by [CONTACT_146532] 1 to 
determine eligibility. NT-proBNP will be measure d in all patients using the central laboratory 
at Visits 2 (randomization), 3, 5, and 7 (Weeks 0, 1, 4, and 8 respectively).
 
 
 
During the COVID-19 pandemic that limits or prevents on-site study visits, or if visits by [CONTACT_348189] a participant’s home are not feasible, the collection of standard chemistry and hematology samples may be modified by [CONTACT_348190].For the primary endpoint biomarkers (Week s 4 and 8), alternative methods of collecting and 
ensuring shipment of biomarkers to the central laboratory should be implemented.  Alternative methods must comply with guidance issued by [CONTACT_669455].
 
 
 
Evaluation of neprilysin measurement at baseline as a predictor of clinical outcome may be 
added depending on availability of a validated assay and sample handling requirements. The list may be changed or expanded further as new relevant biomarkers may be discovered during this study and after its completion. As such, serum and plasma will be bio-banked for analysis of yet to be identified diagnostic biomarkers.  Details of sample collection, handling and shipment will be provided to investigators in the laboratory manual.
8.3.[ADDRESS_904101] for the evaluation of therapeutic agents in a heart failure population.
8.4 Safety
!Incidence of worsening renal function, defined as an increase in serum creatinine of 
≥0.5mg/dl and worsening of the eGFR by [CONTACT_2669] 25% 
!Incidence of symptomatic hypotension 
!Incidence of hyperkalemia (Potassium >5.5 mEq/l)[COMPANY_003]
P
P
D
[COMPANY_001] Page 53
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Incidence of angioedema 
Safety  assessments will consist of monitoring and recording of all adverse events and serious 
adverse events, evaluation of hematology , blood chemistry  and urine values, regul ar 
measurement of vital signs and the performance of phy sical examinations.
During the COVID -19 pandemic that limits or prevents on-site study  visits,regular phone or 
virtual calls should occur for safet y monitoring and discussion of the participant´s hea lth status 
until the 
participant can again visit the site. If a participant cannot visit the site to have 
pregnancy  tests done, a home urine pregnancy or central lab pregnancy testkitmay beused.
Relevant participants canperform theurine pregnancy testat home at the time of the scheduled visit 
andreport theresult tothesite.Itisimportant thatparticipants areinstructed toperform the urine 
pregnancy  test first and only  if the test result is negative proceed with the administration ofthe
study treatment. A communication process should beestablished with the participant sothatthe
site is informed ofthepregnancy testresults.
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to AE section.
Table 8-2 Assessments & Specifications 
Assessment Specification
Physical 
examinationA com plete ph ysical exam will be performed at Visits 1 , 5, 7,11, 13, 15, 16 and 17
(physical exam at visit 2 to be performed only if randomization visit is done on a 
different calendar date than screening).  It will include the examination of general 
appe arance, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, and vascular and neurological examinations. If indicated 
based on medical history, and/or symptoms, rectal, external genitalia, breast and 
pelvic exams will be performed.
Information for all physical examinations must be included in the source 
documentation at the study site(with the exceptions of pandem ic-related virtual 
visits mentioned above) . Significant findings that are present prior to the informed 
consent must be included in the Relevant Medical History/Current Medical 
Conditions screen on the patient’s eCRF. Significant findings made after informed 
consent which meet the definition of an adverse event must be recorded on the 
Adverse Event eCRF.
Vital signsVital signs will be assessed at every in-person visit,andin cases where the COVID -
[ADDRESS_904102].  Every effort should be made to use the 
same arm for the patient for all vital signs assessments and where possible, the 
same person doing the assessment.   For virtual visits, documentation of any vital 
signs available (e.g. hom e BP cuff results ) should be recorded in the eCRF.
Height and 
weightHeight in centimeters if possible will be measured at Visits 1and [ADDRESS_904103] 0.1 kg without shoes, will be measured at Visits1, 2, 3, 5, 7,11, 13, 
15, 16 and 17. 

[COMPANY_001] Page 54
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Assessment Specification
Waist/hip 
circumferenceWaist/hip circumference to the nearest centimeter will be measured at Visit 1.
AngioedemaAngioedema is a type of abrupt swelling that occurs under the skin and/or mucous 
memb ranes and is often localized to the head, neck, throat, and/or tongue, but may 
occur elsewhere, including the genitalia and intestines. Severe cases may be 
associated with airway  comprom ise. Although, the mechanism  is not fully 
understood, brady kinin has been implicated as the putative mediator. Therefore, 
medications that raise the levels of endogenous brady kinin by [CONTACT_669456], such as ACE, aminopeptidase P, and 
NEP, may result in this potentially dangerous side effect. All suspected cases of 
angioedema, regardless of suspected causality, must be reported. The 
Angioedema Questionnaire must be completed and the Clinical Trial Lead or t heir 
designee must be notified.
If the angioedema event meets SAE criteria, the investigator must ensure that an 
SAE form is completed and submitted to [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623]. 
8.4.1 Laboratory  evaluations
The local hospi[INVESTIGATOR_3491]/or clinic laboratory  will be used for all laboratory  evaluations required 
to determine eligibility . If eligibility  laboratory  assessments were not done during the patient’s 
hospi[INVESTIGATOR_059], samples should be collected and sent to the local laboratory . A central 
laboratory  will be used for analysis of all collected specimens from baseline through the final 
visit. Details on the collections, shipment of samples and reporting of results by [CONTACT_669457].  Results from the local 
hospi[INVESTIGATOR_669416].
Clinically  notable laboratory  findings are defined in Appendix [ADDRESS_904104] be entered on the patient's AE eCRF. If the laboratory  abnormality  is 
the primary  reason for an unforeseen hospi[INVESTIGATOR_669417], then the procedure for rapid notification of SAEs must be followed. 
Likewise, if the laboratory  abnorma lity leads to discontinuation from the study  drug 
(temporaril y or permanently ), the patient must be followed until the abnormality  resolves or 
until it is judged to be permanent. This investigation may include continued monitoring by 
[CONTACT_669458].

[COMPANY_001] Page 55
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Table 8-[ADDRESS_904105] Name
[CONTACT_669476], hematocrit, red blood cell count, white blood cell count with differential 
(Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Bands, Other 
(absolute value preferred , %s are acceptable), and platelet count will be m easured at 
Visits 1(local lab), 2,7,11, 13, 15, 16,and 17 (central lab). Hemoglobin A1c will be 
measured at Visits 2 and 17 (central lab).
ChemistryAssessments required for eligibility that need to be measured at Visit 1 include 
creatinine, potassium, and total bilirubin. Blood urea nitrogen (BUN), glucose, 
creatinine, total bilirubin, AST (SGOT), ALT (SGPT), alkaline phosphatase, sodium, 
potassium, chloride, calcium , total protein, albumin, uric acid, and lipid profile be 
measured at Visits 1 (local lab) , 2, 3, 5, 7, 9, 11, 13, 15 , 16, and 17 (central lab) .
Urinalysis Dipstick- test determination of specific gravity, pH, blood, total protein, bilirubin, 
ketones, and leukocy tes will be measured at Visit 2 (central lab). If dipstick is 
positive, a qualitative mic roscopic determination, including white blood cells high 
power field (W BCs/HPF) and red blood cells high power field (RBCs/HPF) will be 
performed.
Pregnancy 
TestAll female patients of childbearing potential will have a serum pregnancy test (hCG) 
performe d at Visit 1 (local lab) .In addition, these patients will have a urine 
pregnancy test conducted in the local laborator y at Visit s 2, 5, 7, 11, 13, 15, [ADDRESS_904106] discontinue study drug.  
8.4.2 Electrocardiogram (ECG)
A standard [ADDRESS_904107] be recorded on the CRF as either medical history 
and/or adverse events as appropriate.
8.4.[ADDRESS_904108] 
(hCG) performed at Visit 1 (local lab
).  In  addition, these patients will have a urine pregnanc y 
test conducted in the local laboratory  at Visit s 2, 5, 7, 11, 13, 15, [ADDRESS_904109] for the evaluation of patients with heart failure.

[COMPANY_001] Page 56
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
8.[ADDRESS_904110] discontinue study treatment for a given patient if he/she believes that 
continuation would negatively impact the patient's well-being.
Study treatment must be discontinued under the following circumstances:
!Patient/guardian decision
!Pregnancy
!Use of prohibited treatment as per recommendations in the prohibited treatment section
!Any situation in which study participation might result in a safety risk to the patient
!Following emergency unblinding
!Any severe suspected drug related AE at the investigator’s discretionPP
D
[COMPANY_001] Page 57
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Suspected occurrence of angioedema. A patient with any  signs or s ymptoms of clinically  
significant angioedema should be thoroughl y evaluated b y the investigator to determine if 
it constitutes a reason for discontinuation of study  medication.
Depending on the serum potassium, blood pressure, or eGFR, patient may need to have their 
study  drug dose or the dose of another concomitant medication reduced or discontinued; or, 
if appropriate, have potentially  contributing agents adjusted.   Refer to appendices for 
treatment guidelines for hy perkalemia, h ypotension or renal d ysfunction, respectivel y.
If discontinuation of study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the patient ’s premature discontinuati on of study  treatment 
and record this information.
Patient s who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see withdraw of informed consent section,). Where possible, they shou ld return 
for the assessments indicated in the assessment schedule. If they fail to return for these 
assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) should be made 
to contact [CONTACT_102] /pre-designated contact [CONTACT_669459] -up section. This 
contact [CONTACT_18616].
If the patient cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact [CONTACT_10970] , or with aperson pre-designated by [CONTACT_102]. This telephone 
contact [CONTACT_18616].
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
new / concomitant treatments
adverse events/Serious Adverse Events
The investigator must also contact [CONTACT_430346] ’s discontinuation from study  
treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code section.
9.1.2 Withdrawal of informed consent
Patient s may voluntaril y withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a patie nt:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
Every  effort should be made to encourage trial continuation to collect information regarding the 
secondary  clinical endpoints (CV Death, HF Hospit alization, and Urgent HF Visits) during the 
longer term follow -up (Amendment 1 and subsequent versions).

[COMPANY_001] Page 58
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
In thesituation the patient still wants to withdraw , the investigator should make a reasonable 
effort (e.g. telephone, e -mail, letter) to understand the primary  reason for the patient ’s decision 
to withdraw his/her consent and record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_18618] -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient ’s study  withdrawal should be made as detailed in the 
assessment table.
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the analysis of a patient ’s samples until the time of withdrawal) according to applicable 
law.
For US: All biological samples not yet analyzed at the time of withdrawal may still be used for 
further testing/anal ysis in accordance with the terms of this protocol and of the informed consent 
form.
9.1.[ADDRESS_904111] show "due diligence" by 
[CONTACT_268295] , e.g. dates of telephone 
calls, registered letters, etc. A patient should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  [CONTACT_157108]. 
Reasons for earl y termination can include :
Unexpected, significant, or unacceptable safet y risk to patient s enrolled in the study
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data 
Discontinuation of study  drug development
In taking the decision to terminate, [COMPANY_001] will alway s consider patient welfare and safety. 
Should early  termination be necessary , patient s must be seen as soon as possible and treat ed as 
a prematurel
y withdrawn patient . The investigator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to the protection of the 
patient ’s interests. The investigator or sponsor depending on local regulation will be responsible 
for informing IRBs/IECs of the early termination of the trial.

[COMPANY_001] Page 59
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
9.[ADDRESS_904112] -study  treatment
At the study  completion/ end of study  visit, patient swill be asked to return all remaining study 
drug.  The investi gator must provide follow -up medical care for all patient s who are prematurel y 
withdrawn from the study , or must refer them for appropriate ongoing care. When the patient
has completed all scheduled study assessments, the investigator must call the IRTtorecord the 
patient completion in the IRT.
Study  completion is defined as when the last patient finishes their Study  Completion visit and 
any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by [CONTACT_669460], in the event of an early study termination decision, the date 
of that decision (e.g. Each patient will be required to complete the study in its entirety  and 
thereafter no further study  treatment will be made available to them) .
The PARAGON -HF Post Trial Access Program (PTA) was stopped after the results of 
PARAGON -HF became known. The primary endpoint was not met; therefore this met the pre -
specified stoppi[INVESTIGATOR_669418]. In view of the discontinuation of the PTA program for 
PARAGON -HF, the company , after careful deliberation, decided to close the PTA for all 
Entresto HFpEF trials, including PARAGLIDE -HF.  This means that the PTA for 
PARAGLIDE- HF, as documented in the Original Protocol Version 00, will no longer be offere d 
to patients enrolled in PARAGLIDE -HF.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual patient and 
identify ing adverse events.
[COMPANY_001] qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105] -directive questioning of the patient at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the patient during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to 
Section 10.1.2):

[COMPANY_001] Page 60
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
1.The severit y grade :
Mild: usually  transient in nature and generally  not interfering with normal activities
Moderate: sufficiently  discomforting to interfere with normal activities
Severe: prevents normal activities
2.its relationship to the study  treatment.  If the event is due to lack of efficacy  or progression 
of underl ying illness (i.e. progression of the study indication) the assessment of causality 
will usually  be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a 
lack of efficacy  or progression of underl ying illness are not caused by [CONTACT_6645], they 
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and progression of 
underly ing disease can only be evaluated meaningfull y by [CONTACT_6646], not on a 
single patient
3.its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.action taken regarding with study  treatment
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug interrupted/withdrawn
6.its outcome (i.e. recovery status or whether it was fatal)
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the patient.
Adverse events (including lab abnormalities thatconstitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least [ADDRESS_904113] be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspecte d relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator ’sBrochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant

[COMPANY_001] Page 61
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_286813] s with 
the underl ying disease. Alert ranges for laboratory a nd other test abnormalities are included in 
Appendix 1 .
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) ormedical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the patient was at 
risk of death at the time of the reaction; it does not refer to a reaction that hypothetically 
might have caused death if it were more severe (please refer to the ICH-E2D 
Guidelines).
results in persistent or significant disability /incapacity
const itutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
routine treatment or monitoring of the studied indication, not associated with any 
deterioration in con dition 
elective or 
pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_064] ’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Such events should be 
considered as “medicall y significant ”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guideline s).

[COMPANY_001] Page 62
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study  indication.
Any suspected transmission via a medicinal prod uct of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
10.1.[ADDRESS_904114] be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics comm ittees in accordance with EU Guidance 
2011/C 172/[ADDRESS_904115] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.

[COMPANY_001] Page 63
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Pregnancy  should be recorded and reported by [CONTACT_37288]  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment and
any pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monito ring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Study 
Treatment eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Reporting angioedema- like events
It is important that the investigator pays special attention to any swelling or edema that may 
resemble angioedema or angioedema -like events that may be reported by [CONTACT_4676] s, including 
during pandemic -related virtual visits when video allows assessment (video is the preferred 
method for virtual visits) . If such an event occurs, the investigator will complete a Questionnair e 
for an Angioedema -like Event form (provided by [CONTACT_5343]) to summarize the event, its 
treatment, and its ultimate outcome and communicate this report to [COMPANY_001] as soon as possible. 
Occasionall y, the investigator may be contact[CONTACT_669461] -like event. The investigator or 
his/her delegated staff must complete the required report forms and supply  the required medical 

[COMPANY_001] Page 64
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
records for such events, regardless of whether the investigator views the event in question as 
angioedema or not.
Submission of an angioedema report is not a substitution for the submission of a SAE report. If 
an angioedema -like event satisfies the definition of a SAE, the investigator must submit a SAE
report in addition to the Questionnaire for an Angioedema -like Event.
10.2.2 Data Monitoring Committee
An external data monitoring committee (DMC) independent of [COMPANY_001] will be appointed to 
review the incidence of the pre-specified clinical events including major cardiac events, serious 
adverse events, the rate and distribution of adverse events, and relevant laboratory  findings on 
an ongoing basis .
The membership of the DMC and the responsibilities of the DMC and [COMPANY_001] will be defined 
in a separate docume nt entitled ‘Data Monitoring Committee Charter’. The DMC Charter will 
include information about data flow, purpose and timing of DMC meetings, guidance in the 
decision making process, communication strategy , procedures for ensuring confidentialit y, 
procedu re to address conflicts of interest and statistical monitoring guidelines.
The DMC will review and make recommendations to the sponsor on whether and how to 
continue the protocol.
10.2.3 Steering Committee
The Steering Committee (SC) will be established comprising investigators participating in the 
trial, i.e. not being members of the DMC and [COMPANY_001]/sponsor representatives from the Clinical 
Trial Team.
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publications of study  results including authorship rules. The 
details of the role of the steering committee will be defined in the ‘Steering Committee Charter ’ .
10.2.4 Adjudication committee s
Endpoint Adjudication Committee: The role of the Endpoint Adjudication Committee (EAC) 
is to ensure that all clinical outcomes are judged uniformly , using standard criteria and processes. 
The EAC will be composed of independent clinical experts to evaluate disease progression and 
harmonize endpoint assessment criteria using data provided b y the sponsor.
All deaths, ( re-)hospi[INVESTIGATOR_059] s, and urgent HF visits will be adjudicated.
All personnel involved in the adjudication process will remain blinded to treatment allocation 
throughout the trial. Specific details regarding endpoint definitions can be found in the 
adjudication charter.

[COMPANY_001] Page 65
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
11 Data collection and database management
11.1 Data collection
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs will be built using fully  validated secure web -enabled 
software that conforms to [ADDRESS_904116] been trained. Automatic validation programs check 
for data discrepanci es in the eCRFs, allow modification and/or verification of the entered data 
by [CONTACT_6649].
Data not requiring a separate written record will be defined in the protocol and the Assessment 
Schedule ( Table 8 -1) and can be recorded directl y on the CRFs. All other data captured for this 
study  will have an external originating source (either written or electronic) with the CRF not 
being considered as source .
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
The investigator/designee is responsible for assuring that the data entered into eCRF sare
complete, accurate, and that entry  and updates are performed in a timely  manner. The 
Investigator must c ertify  that the data entered are complete and accurate .
After final database lock, the investigator will receive copi[INVESTIGATOR_286744].
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investiga tional site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical Dictionary  for Regulatory  Activities (MedDRA) terminology .
Randomiz ation codes and data about all study  treatment (s) dispensed to the patient and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] (or a designated CRO) at specific timelines.
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001].
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data anal ysis/moved to restricted area to be accessed by  [CONTACT_669462] 66
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
and statistician. Anychanges to the database after that time can only be made after written 
agreement by  [CONTACT_232141].
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] and 
UBC representative will review the protocol and data capture requirements (i.e. eCRFs) with 
the investigators and their staff. During the study , [COMPANY_001] employ s several methods of 
ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. The field 
monitor will visit the site to check the completeness of patient records, the accuracy  of data 
capture / data entry , the adherence to the protocol and to Good Clinical Practice, the progress 
of enrollment, and to ensure that study  treatment is being stored, dispensed, and accounted for 
according to specifications. Key study personnel must be available to assist the field monitor 
during these visits. Continuous remote monitoring of each site’s data may be performed by a 
centralized UBC CRA organization. Additionally, a central anal ytics organization may anal yze 
data & identify  risks & trends for site operational parameters, and provide repor ts to [COMPANY_001] 
clinical teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
informat ion, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient ’s file. The investigator must also keep the original informed consent form signe d by [CONTACT_4677] (a signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verifi cation for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
patient s will be disclosed.
[ADDRESS_904117] a two -sided alternative h ypothesis, employ ing a 
significance level of 0.05. 
The final analy siswill be conducted on all participant data at the end of the study . 
Details on data analy sis will be included in the Statistical Analy sis Plan (SAP) and will be 
finalized before the database lock.
Any data analy sis carried out independently  by [CONTACT_669463].

[COMPANY_001] Page 67
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
12.1 Analysis sets
The Randomized Analysis Set (RAN) consists of all randomized participants.
The Full Analysis Set (FAS) comprises all participants to whom study treatment has been 
assigned by [CONTACT_17628]. According to the intent-to-treat principle, participants will be 
included for analysis according to the treatment they have been assigned to during the 
randomization procedure.
The Safety Set (SAF) includes all participants who received at least one dose of study treatment. 
Participants will be included for analysis according to the study treatment they received , where 
treatment received is defined as the randomized treatment if the participant took at least one dose of that treatment or the first study treatment received if the randomized treatment was never received.
The patients in this trial are divided in two groups, (1) Those who are randomized under 
Protocol Version 00 (Original Protocol patients) and (2) Those who are randomized after site execution of Protocol Version 01 (Amendment 1 and subsequent amendment patients).  FAS includes patients from both groups. See Section [ADDRESS_904118] administration of study drug, 
unless specified otherwise. Baseline is labeled as Week 0. Summary statistics will be provided by [CONTACT_669464]/out-of-hospi[INVESTIGATOR_392269].  
Continuous variables will be summarized using n, mean, standard deviation (SD), median, 
minimum, and maximum. Categorical variables will be summarized using frequency and percentage. Additionally, summary statistics will be provided by [CONTACT_669465]/out-of-hospi[INVESTIGATOR_669419]. Geometric means will be used to summarize the NT-proBNP 
. 
Relevant medical history and current medical conditions at Baseline will be summarized by 
[CONTACT_6657], by [CONTACT_1570].
The FAS will be the population for the above analyses. Summary statistics will be provided for 
Original Protocol patients, Amendment 1 patients, and all patients in FAS.
12.3 Treatments
The overall duration of treatment by [CONTACT_669466]/out-of-hospi[INVESTIGATOR_669420], standard deviation, median, minimum, and maximum. Additionally, the number and percentage of participants will be summarized by [CONTACT_669465]/out-of-hospi[INVESTIGATOR_669421]. Concomitant medications and significant non-drug therapi[INVESTIGATOR_014], prior to and after the randomization, will be summarized by [CONTACT_18671], preferred term, treatment group, and in/out-of-hospi[INVESTIGATOR_669422]. The number and percentage of participants on different HFpEF [COMPANY_003]
[COMPANY_001] Page 68
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
background medications (e.g., aldosterone antagonists, β-blockers, diuretics, digoxin) will be 
tabulated by [CONTACT_669467]/out -of-hospi[INVESTIGATOR_669423] y at Baseline and post 
randomization period. The SAF population will be used for the above analyses. 
12.4 Analysis of the primary  endpoint
There is one primary  endpoint.  
Definition of primary  endpoint
The primary  endpoint is the time averaged proportional change in NT-proBNP from Baseline 
to Weeks 4 and 8.
12.4.1 Analysis of the primary  endpoint
The primary  null hypothesis (H10) to be tested is that the ratio of the geometric means of NT-
proBNP (average of Weeks 4 and 8) divided by [CONTACT_669437]/valsartan and 
valsar tan groups are equal versus the alternative h ypothesis (H 1a) that the ratio of the geometric 
means of NT -proBNP are not equal.
First, the arithmetic mean of NT -proBNP at Weeks 4 and 8 will be calculated, then the change 
from baseline in log -transformed NT-proBNP will be calculated as follows: ln(mean post dose 
value) – ln (baseline value). The natural logarithm will be used in all these calculations. This 
log-transformed value will be used as the dependent variable in the analysis of covariance 
(ANCOVA) model described below. This dependent variable is called, the time-averaged 
proportional change from baseline in logarithmic scale. The dependent variable will be analyzed 
using an ANCOVA model with treatment ,in-/out-of-hospi[INVESTIGATOR_392269], gender, and 
baseline LVEF (<= 57%, > 57%) as fixed effect factors , age and the logarithmic baseline NT -
proBNP as covariate s.
The treatment effect in terms of ratios of geometric means is estimated based on the least-
squared means (LS-means) from the ANCOVA model and the corresponding 95% two-sided 
confidence interval will be provided.  Geometric means will be calculated by [CONTACT_669468] L S
-means based on the fitted ANCOVA model.
The FAS will be used in the main anal ysis of the primary  endpoint. 
12.4.2 Handling of missing values/censoring/discontinuations
The analysis will be performed based on all available data in the FAS. Missing values caused 
due to unevaluable samples or earl y discontinuations will not be imputed. I f either the baseline 
value or both Weeks 4 and 8 are missing, then the patient will not be included in the anal ysis.
12.4.3 Sensitivity and Supplementary  Analyses
Sensitivity analy sis
Robustness of the primary  efficacy  results will be explored by [CONTACT_12780][INVESTIGATOR_669424], except the baseline value. Baseline value will 

[COMPANY_001] Page 69
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
not be imputed. When applicable, multiple imputations technique will be considered for 
replacing the missing values. Data will be analyzed using the same ANCOVA model used in 
the primar y analysis.
A second sensitivity  analy sis will be performed based on the Amendment 1 patients only.  The 
analysis will be performed like the main anal ysis of the primary  endpoint.  
Additional sensitivity  analysis will be performed by [CONTACT_669469] -19 
positive status (during the study ) at the patient level.
Supplemental analy sis
In this supplementary  analy sis the variable to be analyzed is: Achieving a pre -
specified percent 
change from baseline in NT-proBNP (bina ry). Three binary  outcome variables will be created 
for patients achieving a 25%, 50% and 75% decline in NT-proBNP (0-no, 1- yes). The dataset 
used in the primary  analysis will be used to define these categorical variables. Also, like the 
primary  analysis, the missing values will not be imputed for this analysis. Logistic regression 
model will be fitted. The odds ratio, confidence interval and p -value will be provided for each 
analysis. The dependent variable will be achieving a target decline in NT-proBNP a
nd the 
predictor of response will be treatment group and in -/out-of-hospi[INVESTIGATOR_669422] .
In addition, anal ysis of the primary  endpoint will be performed with patients randomized after 
Amendment 4 (y es, no) as an additional factor to the model m entioned in Section 12.4.1.
Subgroup analy ses
A set of pre-specified subgroups will be defined in the Statistical Analy sis Plan to assess 
consistency  of the primary  efficacy  result and effect of these s ubgroups on NT -proBNP.
12.5 Analysis of Secondary  Endpoints
12.5.1 Secondary  endpoints 
1.The composite hierarchical outcome consisting of: a) time to CV death, b) number and 
times of HF hospi[INVESTIGATOR_663322] -up, c) number and times of urgent HF visits 
during f ollow -up, and d) time averaged proportional change in NT -proBNP (from baseline 
to Weeks 4 and 8)
2.The cumulative number of recurrent composite events overtime, i.e., the total number of 
composite events of HF hospi[INVESTIGATOR_602], urgent HF visits, and CV death. 
3.Incidences of a composite endpoint of worsening renal function 
defined as: 
renal death
reaching end -stage renal disease (ESRD)
≥ 50% decline in estimated glomerular filtration rate (eGFR) relative to baseline
4. Proportional change in NT- proBNP from Baseline to Week 8 
5. Proportional change in hs- Troponin (high sensitivity ) from baseline to Weeks [ADDRESS_904119] during treatment

[COMPANY_001] Page 70
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Incidence of s ymptomatic hy potension 
Incidence of h yperkalemia (potassium >5.5 mEq/L)  
Incidence of angioedema 
Incidence of worsening renal function, defined as an increase in serum creatinine of 
≥0.5mg/dl and worsening of the eGFR by  [CONTACT_2669] 25% 
Analysis of secondary endpoint 1
This secondary  endpoint will be analy zed estimating the unmatched win ratio by [CONTACT_669470]/valsartan arm to every  participant in the valsartan arm to 
determine a winner (unmatched pairing method). The estimated win ratio (the total numbe r of 
wins in the sacubitril/valsartan arm divided by [CONTACT_669471]) 
will be calculated. The corresponding null and alternative h ypotheses are:
H20: Win ratio is equal to 1, versus 
H2a: Win ratio is not equal to 1. 
A win ratio greater than 1 will be in favor of sacubitril/valsartan arm. This test will be performed 
only if the primary  null hypothesis (H10) is rejected. The testing of hypothesis H20and 
calculation of the corresponding two- sided 95% confidence intervals will b e performed. 
A component will only be used as tie -breaker in the pairwise comparison between two patients 
if the comparison of components with a higher priority  resulted in a tie. For component a) the 
patient with the later time to death in the common follow-up period is the winner. For 
component b) the patient with the smaller number of HF hospi[INVESTIGATOR_669425] -
up period is the winner. If the number of HF hospi[INVESTIGATOR_669425] -up period 
is tied, the patient with the later time of the last HF hospi[INVESTIGATOR_669426] -up 
period is the winner. For component c) the same algorithm is applied as for component b). For 
component d), the patient with the larger decrease or smaller increase in the proportional change 
is considered a winner; if the ratio of the proportional changes from two patients is between 
0.75 and 1/0.75, then the pairwise comparison of the change in NT -proBNP is considered tied.
The analysis will be performed using the unmatched pair win ratio approac h (Pocock et al 2012).  
Contributions of each component of the composite endpoint to to
tal number of winners used in 
estimation of the win ratio will be reported. 
Handling of missing values/censoring/discontinuations
Time to CV death
The time from randomization to CV death will be considered as censored for analysis for 
participants who have not experienced a CV death and for whom at least one of the following 
applies at or prior to the anal ysis time point:
withdrawal of informed consent
loss to follow up
death from non -CV causes

[COMPANY_001] Page 71
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
The censoring date for those participants without CV death prior to the analysis time point will 
be whichever occurs first of the following:
date of withdrawal of informed consent
date of last visit (End of Study  visit)
date of death from non -CV causes
NT-proBNP measurement at Weeks [ADDRESS_904120] the analysis. Missing 
NT-proBNP measurements at Weeks 4 and 8 due to other reasons (e.g., non-CV death) are 
expected to be infrequent; they  may  result in more ties with minimal impact on the power. No 
imputation will be done for missing NT -proBNP measurement at Weeks 4 and 8. 
Analysis of secondary endpoint 2
The cumulative number of composite events, i.e., the total num ber of composite events of CV 
death, recurrent HF hospi[INVESTIGATOR_602], and recurrent urgent HF visits for a patient over time will 
be calculated. The time to these recurrent events will be analyzed using the semi -parametric 
proportional rates model (abbreviat ed as LWYY model) (Lin et 
al 2000). The hypotheses of 
interest are:
H30: Rate ratio of sacubitril/valsartan arm over valsartan arm equal to 1, versus 
H3a: Rate ratio of sacubitril/valsartan arm o ver valsartan arm n ot equal 1. 
A rate ratio < [ADDRESS_904121] in favor of sacubitril/valsartan arm. 
The FAS will be 
used in the main anal ysis of the second key  secondary  endpoint. 
The hypothesis (H30) will be tested and 95% confidence interval will be provided. The rate ratio 
will be estimated from the above proportional rates model through maximization of a partial 
likelihood score function and the confidence intervals will be based on the robust estimate of 
the standard errors. The number and percentage of CV event s by [CONTACT_669472].  
The CV death will not be considered as a censoring variable, but as a composite endpoint event 
and a conditional factor in this analy sis. Time to non-CV death will be considered as a censoring 
variable. An y censoring d
ue to non- CV death is assumed to be non- dependent in the anal ysis. 
Analysis of secondary endpoint 3
The total number of composite events will be analyzed using a negative binomial regression 
model with the count data as the dependent variable.  Treatment group and in/out -of-hospi[INVESTIGATOR_669427] a fixed -effect factors and log(follow -up duration) as the off -set.  The model 
will be used to estimate event rates and their 95% confidence intervals b y treatment group.
The time to the first composite event will be analy zed using Cox’s proportional hazard model 
with factors treatment and in/out -of-hospi[INVESTIGATOR_307] r andomization.  Hazard ratio for treatment and its 
95% confidence interval will be reported. 

[COMPANY_001] Page 72
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Analysis of secondary endpoint 4
The proportional change in NT-proBNP from Baseline to Week 8 will be analyzed using an 
ANCOVA model similar to that of the primary efficacy  anal ysis.
Analysis of secondary endpoint 5
The proportional change in hs-Troponin (high sensitivity ) from baseline to Week 4 will be 
analyzed using an ANCOVA model similar to that of the primary  efficacy  analysis. Log-
transformed hs -Troponin will be used for analysis.  The anal ysis will be repeated for Week 8.
Analysis of secondary endpoint 6
The dosing level will be summarized by [CONTACT_669465]-/out-of-hospi[INVESTIGATOR_669428]. Incidence ofdiscontinuations (all causes) will be summa rized by [CONTACT_669473]-/out-of-hospi[INVESTIGATOR_669429]. 
Analysis of secondary endpoint 7
Incidence of event will be analy zed using logistic regression model with treatment and in/out -
of-hospi[INVESTIGATOR_669430]. The model will be used to estimate the odds ratio for 
treatment and its 95% confidence interval. 
The number (and proportion) of patients with adverse events of special interest will be 
summarized by  [CONTACT_3148], primary  system organ class and preferred term. All these secondary 
endpoints will be anal yzed using FAS and nominal p- values will be reported.  There will be no 
adjustment for multiplicity.
12.5.2 Safety  endpoints
For all safet y anal yses, the safet y set (SAF) will be used.  All listings and tables will be 
presented b y treatment group and in/out - of-hospi[INVESTIGATOR_669422]. 
Safety  summaries (tables, figures) include onl y data from the on -treatment period with the 
exception of Baseline data, will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate listing for death including on - treatment and post-
treatment deaths will be provided. In particular, summary  tables for AEs will summarize only  
on-treatment events, with a start date during the on - treatment period (treatment -emergent 
AEs). 
The on- treatment period lasts from the date of first administration of study  treatment to the 
last study  visit .
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_90217]. 
The number (and percentage) of patients with treatment emergent adverse events (events 
started after the first dose of study  medication, or events present prior to start of double -
masked treatment but increased in severit y based on preferred term) will be summ arized in the 
following way s:

[COMPANY_001] Page 73
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
!By [CONTACT_3148], primary system organ class and preferred term.
!By [CONTACT_3148], primary system organ class, preferred term and maximum severity.
!By [CONTACT_3148], pre-defined topic of interest, primary system organ class and preferred 
term. 
Separate summaries will be provided for study medication related adverse events, serious 
adverse events, and other significant adverse events leading to discontinuation. 
A patient with multiple adverse events within a primary system organ class is only counted 
once towards the total of the primary system organ class.
Vital signs
All vital signs data will be listed by [CONTACT_1570], in/out-of-hospi[INVESTIGATOR_392269], patient, 
and visit/time and if ranges are available, abnormalities will be flagged. Descriptive statistics will be provided by [CONTACT_3148], and visit/time and will be presented graphically.
Clinical laboratory evaluations
All laboratory data will be listed by [CONTACT_1570], in/out-of-hospi[INVESTIGATOR_392269], patient, 
and visit/time and if normal ranges are available abnormalities will be flagged. Summary statistics will be provided by [CONTACT_3148], in/out-of-hospi[INVESTIGATOR_392269], and visit/time. Shift tables using the low/normal/high/ classification will be used to compare baseline to the worst on-treatment value.
12.5.3 Biomarkers
See Sections 12.4 and 12.5 for a description of the methods used to analyze the biomarkers.  
 
 
 
 
 [COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_001] Page 74
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
[COMPANY_003]
[COMPANY_001] Page 75
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
12.7 Interim analysis
There is no planned interim analysis for efficacy in the study. 
An independent Data Monitoring Committee (DMC) will be responsible for performing interim 
safety assessment using independent statistician and programmer who will not be involved in 
the trial conduct. The DMC charter will contain the committee’s responsibilities regarding the interim safety assessment. Details of this safe ty assessment will be included in the Statistical 
Analysis Plan.
Interim safety assessments are planned to be performed and results will be provided to DMC 
for their review and recommendation.  The number and/or timing of these safety assessments will be mentioned in the Data Monitoring Committee Charter. No adjustment of the level of significance will be made for these interim safety assessments.
12.8 Sample size and Power
The target sample size for this study is approximately 450 total patients (including original protocol and all Amendment patients), randomized in the two treatment groups in 1:[ADDRESS_904122] 85% power to detect a 23% reduction in the 
geometric mean of the proportional change from baseline to an average of Weeks 4 and 8 in NT-proBNP for the sacubitril/valsartan treatment group. This 23% reduction in geometric mean is equivalent to -0.2614 in natural log scale (= ln(0.77) ). The power is estimated assuming a two-
sided significance level of 0.05, a common standard deviation of 0.85 for change in log transformed NT-proBNP and a 15% rate of missingness in NT-proBNP at both Week4 and Week8. nQuery Version [IP_ADDRESS] (2019) software package is used in calculating the power of the test.
13 Ethical considerations and administrative procedures
13.1 Regulatory and ethical compliance
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki.[COMPANY_003]
[COMPANY_001] Page 76
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, patient recruitment procedures (e.g., 
advertisements) and any other written information to be provided to patient s(e.g., patient 
materials and thank you letters) . Prior to study  start, the investigator is required to sign a 
protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with 
these documents and all of the instructions and procedures found in this protocol and to give 
access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Qualit y 
Assurance representatives, designated agents of [COMPANY_001] , IRBs/IECs, and regulatory  authorities 
as required. If an inspection of the clinical site is requested by a  regulatory  authority , the 
investigator must inform [COMPANY_001] immediately  that this request has been made.
13.[ADDRESS_904123]. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitte d for publication and 
posted in a publicly  accessible database of clinical trial results, such as the [COMPANY_001] clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.) .
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings.
13.[ADDRESS_904124] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based app roach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes
[ADDRESS_904125] any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despi[INVESTIGATOR_131313], data, information, 

[COMPANY_001] Page 77
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
[COMPANY_001] and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_18686] B/IEC and health authorities, where required, it cannot be implemented.
14.[ADDRESS_904126] be approved by [CONTACT_5343] , health authorities where required, and theIRB/IEC prior to 
implementation.
Only  amendments that are required for patient safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding theneed for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Page 78
Amended Protocol Version No. 04 (clean)                                                 Protocol No. CLCZ696DUS01
[ADDRESS_904127]
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized 
monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol2001;108:184-90.
Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac 
function heart failure with an aldosterone antagonist trial: A randomized, controlled study of 
spi[INVESTIGATOR_669431]. Am Heart J 2011;162:966-972.
Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in 
patients with chronic kidney disease. Circulation [ADDRESS_904128] 9;138(15):1505-1514.
Kristensen SL, Jhund PS, Kober L, et al. Relative importance of history of heart failure 
hospi[INVESTIGATOR_5478] N-Terminal Pro-B-Type Natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2015; 3:478-86.
Levey AS, Coresh J, Greene T, et al.  Expressing the modification of diet in renal disease 
study equation for estimating glomerular filtration rate with standardized serum creatinine 
values.  Clin Chem 2007;53:766-72.
Lin DY, Wei LJ, Yang I, et al. Semiparametric regression for the mean and rate functions of 
recurrent events. J Royal Stat Soc: Ser B (Stat Methodol) 2000; 62: 711–730.
Mao, L. and Lin, D.Y., 2016. Semiparametric regression for the weighted composite endpoint 
of recurrent and terminal events. Biostatistics, 17(2), pp.390-403.
McCullagh P, Nelder JA. (1989) Generalized Linear Models, 2nd ed. London: Chapman and
Hall.
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure (2012): The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
McMurray JV, Packer M, Desai AS, et al.  Angiotensin-neprilysin inhibition versus enalapril 
in heart failure. N Engl J Med 2014;371:993-1004.
Packer M, McMurray JV, Desai AS, et al.  Angiotensin receptor neprilysin inhibition 
compared with enalapril on the risk of clinical progression in surviving patients with heart 
failure. Circulation 2015;131:54-61.
Pocock, S.J., Ariti, C.A., Collier, T.J. and Wang, D., 2012. The win ratio: a new approach to 
the analysis of composite endpoints in clinical trials based on clinical priorities. European 
Heart Journal ,33(2), pp.176-182.[COMPANY_003]
[COMPANY_001] Page 79
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Solomon SD, McMurray  JJV, Anand I S, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer 
M, Pfeffer MA, Pi[INVESTIGATOR_88082] B, Redfie ld MM, Rouleau JL , van Veldhuisen DJ, Zannad F, Zile MR, 
Desai AS, Claggett B, Jhund PS, Boy tsov SA, Comin- Colet J, Cleland J, Düngen HD, 
Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkel y B, Senni M, Shah SJ, Zhou 
J, Rizkala AR, Gong J, Shi VC, L efkowit z MP.  Angiotensin- Neprily sin Inhibition in Heart 
Failure with Preserved Ejection Fraction. N Engl J Med. [ADDRESS_904129] 24;381(17):[ADDRESS_904130] ion fraction – rationale and design of the PARAGON -HF trial.  
JACC Heart Failure 2017;5:471-82.
Solomon SD, Rizkala AR, L efkowitz MP, et al.  Baseline characteristics of patients with heart 
failure and preserved ejection fraction in the PARAGON -HF trial.  Circ Heart Fail 
2018:11:e004962  DOI -10.1161.
Solomon SD, Zile M, Pi[INVESTIGATOR_88082] B, et al. The angiotensin receptor nepril ysin inhibitor L CZ696 in 
heart failure with preserved ejection fraction: a phase 2 double -blind randomised controlled 
trial. Lancet 2012;380:1 387-1395.
Velazquez EJ, Morrow DA, DeVore AD, Duffy  CI, Ambrosy  AP, McCague K, Rocha R, 
Braunwald E. Angiotensin- nepril ysin inhibition in acute decompensated heart failure. NEJM 
2018 DOI:10.1056/NEJMoa1812851.
Wachter R et al. Initiation of sacubitril/vals artan in hospi[INVESTIGATOR_669432]: Primary  results of the 
TRANSI TION stud y. Data presented at: ESC 2018, Aug 25 -29; Munich, [LOCATION_013] .
Yancy  CW, Jessup M, Bozkurt B, et al.  2013 ACCF/AHA Guidelines for the management of 
heart failure.  Report of the American College of Cardiology  Foundation/American Heart 
Association Task Force on Patient Guidelines. Circulation 2013;128:e240 -e327.

[COMPANY_001] Page 80
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
16 Appendices
16.1 Appendix 1: Clinically  notable laborat ory values and vital signs
Clinically  notable laboratory  abnormalities for selected tests based on a percent change from 
baseline:
Hematology
RBC count >50% increase, >20% decrease
Hemoglobin >50% increase, >20% decrease
Hematocrit >50% increase, >20% d ecrease
WBC count >50% increase, >50% decrease
Platelet count >75% increase, >50% decrease
Blood Chemistry
ALT (SGPT) >150% increase
AST (SGOT) >150% increase
BUN >50% increase
Creatinine >50% increase
Total bilirubin >100% increase
CPK >300% increase
Alkaline phosphatase >100% increase
Potassium >20% increase, >20% decrease
Chloride >10% increase, >10% decrease
Calcium >10% increase, >10% decrease
Uric acid >50% increase

[COMPANY_001] Page 81
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
16.2 Appendix 2: Treatment guidelines for hy perkalemia (serum 
potassium greater than or equal to 5.5 mEq/L)
General principles
Elevation of potassium levels above the predefined values should be repeated and confirmed 
before any action is taken.
Any patient who experiences a potassium level ≥ 5.5 mEq/L confirmed by [CONTACT_669474], repeated checks of potassium concentration (beyond that 
prescribed in the protocol) until it is clear that the potassium concentration is stable and not 
rising into the range of concern ( ≥ 5.5 mEq/L) . 
Patients with elevated potassium value will be managed according to the corrective actions 
outlined below and the investigator’s clinical judgement . Hyperkalemia should be followed 
until resolution.
Recommended c orrective action for management of hy perkalemia
Serum p otassium > 5.3 and less than or equal to 5.5 mEq/L
Confirm potassium concentration in a non -hemoly zed sample
Reinforce low potassium diet and restriction of food/drinks with high potassium content 
(e.g. orange juice, melon, bananas, low -salt substitutes et c.) 
Review medical regimen (including dietary  supplements and over -the-counter 
medications) for agents known to cause h yperkalemia. Consider reduction in dose or 
discontinuation of these agents:
Aldosterone antagonists (if they  are believed to be the most likely  cause of hy perkalemia)
Potassium -sparing diuretics (e.g. amiloride and triamterene) including in combination 
products with thiazide or loop diuretics 
Potassium supplements, e.g., potassium chloride
Salt substitutes 
Non-steroidal anti -inflammatory drugs (NSAIDs)
Cyclo-oxygenase -2 (COX -2) inhibitors
Trimethoprim and trimethoprim -containing combination products, such as Bactrim®and 
Septra®(trimethoprim/sulfamethoxazole fixed combination)
Herbal Supplements:
For example, Noni juice, alfalfa ( Medicago sativa ), dandelion ( Taraxacum officinale ), 
horsetail ( Equisetum arvense ), nettle ( Urtica dioica ), milkweed, lily  of the valley , Siberian 
ginseng, hawthorn berries
Repeat serum potassium measurement within 3 to 5 day s
If serum potassium remains > 5.3 and ≤ 5.5 mEq/L , regularl y monitor serum potassium
levels to ensure stability  (suggested once monthly)

[COMPANY_001] Page 82
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
Consider down- titration of study  medication, according to investigator’s medical 
judgment.
Serum potassium > 5.5 and < 6.0 mEq/L
Confirm potassium con centration in a non -hemoly zed sample 
Consider down- titration or temporaril y discontinue study  drug according to investigator 
medical judgment. 
Apply  all measures outlined for serum potassium > 5.3 and ≤ 5.5 mEq/L
Repeat serum potassium measurement after 2-3 day s
If serum potassium < 5.5 mEq/L , consider resumption of study  drug at lower dose with 
repeat potassium within 5 days
Serum potassium greater than or equal to 6.0 mEq/L
Immediately  discontinue study  drug
Confirm potassium concentration in a non -hemoly zed sample
Urgently  evaluate patient and treat hy perkalemia as clinically  indicated 
Apply  all measures outlined for serum potassium > 5.3 and < 6.0 mEq/L
If serum potassium < 5.5 mEq/L , consider resumption of study  drug at lower dose with 
repeat potassi um within 5 day s

[COMPANY_001] Page 83
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
16.3 Appendix 3: Guidelines for the management of blood pressure
Guidelines
1.Investigator should monitor blood pressure closely 
2.If symptomatic hy potension occurs:
a.Correct an y treatable cause, e.g. h ypovolemia
b.If hypotension persists, any antihy pertensive drug and non -disease -modify ing 
drugs, such as diuretics, CCBs, nitrates, and α -blockers, should be down -titrated or 
stopped first before down- titration of the study  drug is considered
3.If hypotension persists, the study drug should be down -titrated or even temporarily  
withdrawn. The dose re -challenge and medication adjust ment guidelines described in 
Section 6.4.1 should be adhered to as much as possible .
16.4 Appendix 4: Guidelines for the managemen t of renal dy sfunction
General principles:
Glomerular filtration rate in HF patients depends on intrinsic renal function and on a balance 
between afferent and efferent glomerular arterial tonicity . This tonicity  is partly  regulated by  a 
stimulation of angi otensin II and could be affected by  [CONTACT_18690]. Moreover, renal 
dysfunction may develop or may deteriorate in some patients after study  drug administration. 
These recommendations have been developed to guide the investigators in managing patie nts 
with renal d ysfunction after randomization.
Two types of response to serum creatinine increase are described:
Surveillance situation 
If, at any time after randomization, eGFR decreases by ≥ 25% from baseline (or if serum 
creatinine concentration incre ase to 2.5 mg/dL [221 µmol/L ]), the investigator will check for 
potentially  reversible causes of renal dy sfunction such as:
Non-steroidal anti -inflammatory  drug intake, antibiotics, or other treatments known to 
affect creatininemia
Volume decrease, including that resulting from excessive dosing of diuretics
Urinary  infection
Urinary  tract obstruction
Study  medication
Action situation 
If a patient eGFR decreases by ≥ 40% from baseline (or if serum creatinine concentration rises 
above 3 mg/dL (265 µmol/L ), the investigator will check for potentiall y reversible causes of 
renal d ysfunction (see above).

[COMPANY_001] Page 84
Amended Protocol Version No. 0 4 (clean)                                                 Protocol No. CLCZ696DUS01
If the investigator judges that study  medication has to be stopped, he/she will have to contact 
[CONTACT_146553]/her designee. Thereafter, serum creatinine assessments will 
have to be repeated at least each week until levels return to acceptable values. If study 
medication was stopped, every  effort will be done to restart it again, according to clinical 
conditions.

[COMPANY_001] Page 85
Amended Protocol Version No. 0 4 (clean ) Protocol No. CLCZ696DUS01
16.5 Appendix 5: Expanded A ssessment Schedule
Period Screening Double -Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study  
Compl
etion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 
3Visit 
48Visit 5 Visit 
67Visit 
7Visit 
87Visit 
98Visit 
108Visit 
11Visit 
128Visit 
13Visit 
148Visit 
15Visit 
16Visit 
17
Week
(Day) [Day -30 
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 
7)2 
(Day 
14)4 
(Day 
28)6
(Day 
42)8
(Day 
56)10
(Day 
70)12
(Day 
84)16
(Day 
112)24
(Day 
168)32
(Day 
224)40
(Day 
280)48
(Day 
336)56
(Day 
392)68 
(Day 
476) 84
(Day 
588)
Information and 
informed consentS
Inclusion/exclusion 
criteriaX X
Demography / 
Medical historyX
Heart failure and 
CV disease historyX
ECG X
Physical Exam S S S S S S S S S S S S
Height X X
Weight X X X X X X X X X X X X X X X X X
Waist/hip 
circumferenceX
Vital Signs X X X X X X X X X X X X X X X X X
HF signs and 
symptoms and 
NYHA classificationX X X X X X X X X X X X X X X X X

[COMPANY_001] Page 86
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 
3Visit 
48Visit 5 Visit 
67Visit 
7Visit 
87Visit 
98Visit 
108Visit 
11Visit 
128Visit 
13Visit 
148Visit 
15Visit 
16Visit 
17
Week
(Day) [Day -30 
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 
7)2 
(Day 
14)4 
(Day 
28)6
(Day 
42)8
(Day 
56)10
(Day 
70)12
(Day 
84)16
(Day 
112)24
(Day 
168)32
(Day 
224)40
(Day 
280)48
(Day 
336)56
(Day 
392)68 
(Day 
476) 84
(Day 
588)
Heart failure and 
CV medicationsXX4X XX XX X XX XX XX X X
Chemistry labs X X X XX X X3X X X XXX
Hematology labs X X X X X X XXX
Hemoglobin A1C X X
eGFR X X X XX X X3X X X XXX
Urinalysis X
Pregnancy Test2XX X X X XX XX XX X X
IRT X X X XX XX X X XX XX XX X X
Randomization X
Plasma NT-
proBNP or BNP X5XX X X
hs-Troponin X X X
Drug accountability X XX XX X X XX XX XX X X
Dispense study 
treatment XX XX XX X X XX XX XX X
Concomitant 
medicationsXX X XX XX X X XX XX XX X X[COMPANY_003]
[COMPANY_001] Page 87
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 
3Visit 
48Visit 5 Visit 
67Visit 
7Visit 
87Visit 
98Visit 
108Visit 
11Visit 
128Visit 
13Visit 
148Visit 
15Visit 
16Visit 
17
Week
(Day) [Day -30 
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 
7)2 
(Day 
14)4 
(Day 
28)6
(Day 
42)8
(Day 
56)10
(Day 
70)12
(Day 
84)16
(Day 
112)24
(Day 
168)32
(Day 
224)40
(Day 
280)48
(Day 
336)56
(Day 
392)68 
(Day 
476) 84
(Day 
588)
Adverse events / Serious Adverse eventsXX X
XX XX X X XX XX XX X X
Angioedema 
assessmentXX X XX XX X X XX XX XX X X
Thank You letter X X
Study completion –
randomized treatmentX
Post study completion follow up S6[COMPANY_003]
[COMPANY_001] Page 88
Amended Protocol Version No. 04 (clean) Protocol No. CLCZ696DUS01
Period Screening Double-Blind Treatment 
(84 week)
Visit Name [CONTACT_669475]/Baseline Study 
Completion/
End of 
Study
Visit Number Visit 1 Visit 2 Visit 
3Visit 
48Visit 5 Visit 
67Visit 
7Visit 
87Visit 
98Visit 
108Visit 
11Visit 
128Visit 
13Visit 
148Visit 
15Visit 
16Visit 
17
Week
(Day) [Day -30 
to -1.5 
(36hours)]0 
(Day 1)1 
(Day 
7)2 
(Day 
14)4 
(Day 
28)6
(Day 
42)8
(Day 
56)10
(Day 
70)12
(Day 
84)16
(Day 
112)24
(Day 
168)32
(Day 
224)40
(Day 
280)48
(Day 
336)56
(Day 
392)68 
(Day 
476) 84
(Day 
588)
X = assessment to be recorded in the clinical database or received electronically from a vendorS = assessment to be recorded in the source documentation and in the database
 
2All female patients of childbearing potential will have a serum pregnancy test (hCG) performed at Visit 1 (local lab). A urine pregnancy test will be conducted in the local laboratory for 
remaining visits.
3Limited chemistry panel. eGFR will be calculated from creatinine concentration.
4CV medications will be recorded at time of hospi[INVESTIGATOR_2345].
5BNP or NT-proBNP will be assessed at Visit 1 via local laboratory. Only NT-proBNP will be assessed via central laboratory for V isits 2, 3, 5 and 7.
6Health status phone call 4 weeks after study completion.
7 Visits are applicable to Original Protocol Version 00, but are not applicable for patients following Amended Protocol Version 01  and all subsequent amendments.
8Visits are applicable to Amended Protocol Version 03, but are not applicable for patients following Amended Protocol Version 04 and all subsequent amendments.P